

Identification and Biological Activity of the Active Meta

Thrombosis and Haemostasis

84, 891-896

DOI: 10.1055/s-0037-1614133

Citation Report

#	ARTICLE	IF	CITATIONS
1	Use of Radiolabeled 2-Methylthio-ADP to Study P2Y Receptors on Platelets and Cell Lines. , 2004, 273, 115-124.		5
2	P2Y12, a New Platelet ADP Receptor, Target of Clopidogrel. Biochemical and Biophysical Research Communications, 2001, 283, 379-383.	1.0	219
3	Pharmacological control of platelet function. Pharmacological Research, 2001, 44, 255-264.	3.1	35
4	Clopidogrel. American Journal of Cardiovascular Drugs, 2001, 1, 467-474.	1.0	6
5	Platelet pharmacology. , 2001, , 341-366.		0
6	Plateletâ€“leukocyteâ€“endothelium cross talk. , 2001, , 106-123.		3
7	Platelet-Active Drugs. Chest, 2001, 119, 39S-63S.	0.4	569
8	How to Get From Antiplatelet to Antithrombotic Treatment. American Journal of Therapeutics, 2001, 8, 443-449.	0.5	23
9	ADP Receptors of Platelets and their Inhibition. Thrombosis and Haemostasis, 2001, 86, 222-232.	1.8	375
10	Protease-activated Receptors in Vascular Biology. Thrombosis and Haemostasis, 2001, 86, 298-307.	1.8	212
11	Identification, Characterization, and Inhibition of the Platelet ADP Receptors. International Journal of Hematology, 2001, 74, 375-381.	0.7	49
12	Novel Tricyclic Benzothiazolo[2,3- c]thiadiazine Antagonists of the Platelet ADP Receptor (P2Y 12). Bioorganic and Medicinal Chemistry Letters, 2001, 11, 1805-1808.	1.0	34
13	Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers. British Journal of Clinical Pharmacology, 2001, 52, 333-336.	1.1	150
14	Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature, 2001, 409, 202-207.	13.7	1,338
15	Role of ADP Receptor P2Y12in Platelet Adhesion and Thrombus Formation in Flowing Blood. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 686-691.	1.1	111
16	Antiplatelet strategies*1. European Heart Journal Supplements, 2002, 4, A42-A47.	0.0	7
17	Effect of Clopidogrel on Platelet Aggregation and Plasma Concentration of Fibrinogen in Subjects With Cerebral or Coronary Atherosclerotic Disease. Clinical and Applied Thrombosis/Hemostasis, 2002, 8, 381-382.	0.7	1
18	Chapter 8. Purine and pyrimidine nucleotide (P2) receptors. Annual Reports in Medicinal Chemistry, 2002, 37, 75-84.	0.5	0

#	ARTICLE	IF	CITATIONS
19	Purine and Pyrimidine (P2) Receptors as Drug Targets. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 4057-4093.	2.9	334
20	Acyclic Analogues of Adenosine Bisphosphates as P2Y Receptor Antagonists: A Phosphate Substitution Leads to Multiple Pathways of Inhibition of Platelet Aggregation. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 5694-5709.	2.9	79
21	Supercritical Fluid and Unified Chromatography. <i>Analytical Chemistry</i> , 2002, 74, 2801-2812.	3.2	47
22	Structure and Stereochemistry of the Active Metabolite of Clopidogrel. <i>Drug Metabolism and Disposition</i> , 2002, 30, 1288-1295.	1.7	408
23	Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. <i>Platelets</i> , 2002, 13, 407-413.	1.1	140
24	Les r�cepteurs P2Y des nucl�otides extracellulaires : du clonage � la physiologie. <i>Medecine/Sciences</i> , 2002, 18, 965-973.	0.0	6
25	Platelet receptors: ADP. , 2002, , 127-139.		2
26	P2 Receptors and Platelet Activation. <i>Scientific World Journal, The</i> , 2002, 2, 424-433.	0.8	20
27	Antiplatelet Therapy and Coronary Interventions: Childhood Friends or Permanent Partners?. <i>Journal of Interventional Cardiology</i> , 2002, 15, 41-42.	0.5	0
28	Antiplatelet Therapy and Coronary Interventions: Childhood Friends or Permanent Partners?. <i>Journal of Interventional Cardiology</i> , 2002, 15, 111-113.	0.5	0
29	Mechanisms of platelet retention in the collagen-coated "bead column. <i>Translational Research</i> , 2003, 142, 258-267.	2.4	9
30	Acute coronary disease Athero-Inflammation: Therapeutic approach. , 2003, 1, 2.		10
31	Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. <i>Journal of the American College of Cardiology</i> , 2003, 41, S79-S88.	1.2	85
32	Clopidogrel's role in the management of atherosclerotic disease: a focus on acute coronary syndromes. <i>Expert Review of Cardiovascular Therapy</i> , 2003, 1, 507-522.	0.6	0
33	The role of clopidogrel in the management of acute coronary syndromes. <i>Clinical Therapeutics</i> , 2003, 25, 2155-2181.	1.1	9
34	Platelet purinergic receptors. <i>Current Opinion in Pharmacology</i> , 2003, 3, 175-180.	1.7	140
35	Platelets, atherosclerosis and the endothelium: new therapeutic targets?. <i>Expert Opinion on Investigational Drugs</i> , 2003, 12, 1765-1776.	1.9	15
36	Are Antiplatelet Effects of Clopidogrel Inhibited by Atorvastatin?. <i>Circulation</i> , 2003, 107, 1568-1569.	1.6	36

#	ARTICLE	IF	CITATIONS
37	Pharmacological Characterization of the Human P2Y ₁₃ Receptor. <i>Molecular Pharmacology</i> , 2003, 64, 104-112.	1.0	223
38	Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation. <i>Circulation</i> , 2003, 107, 32-37.	1.6	656
39	The Effect of a Loading Dose (300 mg) of Clopidogrel on Platelet Function in Patients with Peripheral Arterial Disease. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2003, 9, 115-120.	0.7	27
40	Both the ADP receptors P2Y ₁ and P2Y ₁₂ , play a role in controlling shape change in human platelets. <i>Platelets</i> , 2003, 14, 15-20.	1.1	50
41	The Metabolism of Clopidogrel Is Catalyzed by Human Cytochrome P450 3A and Is Inhibited by Atorvastatin. <i>Drug Metabolism and Disposition</i> , 2003, 31, 53-59.	1.7	354
42	Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function – a flow cytometry study. <i>European Heart Journal</i> , 2003, 24, 1744-1749.	1.0	167
43	Antiplatelet Agents in Acute Coronary Syndromes. <i>Seminars in Vascular Medicine</i> , 2003, 03, 403-414.	2.1	4
44	P2Y ₁₂ , A New Platelet ADP Receptor, Target of Clopidogrel. <i>Seminars in Vascular Medicine</i> , 2003, 03, 113-122.	2.1	93
45	Clopidogrel: Interactions with the P2Y ₁₂ Receptor and Clinical Relevance. <i>Hematology</i> , 2003, 8, 359-365.	0.7	16
46	Platelets and Anti-platelet Therapy. <i>Journal of Pharmacological Sciences</i> , 2003, 93, 381-396.	1.1	88
47	ADP receptor antagonists as antiplatelet therapeutics. <i>Expert Opinion on Emerging Drugs</i> , 2003, 8, 93-101.	1.0	10
48	Enzymatically catalyzed disulfide exchange is required for platelet adhesion to collagen via integrin $\alpha_2\beta_1$. <i>Blood</i> , 2003, 102, 2085-2092.	0.6	158
49	Inactivation of the human P2Y ₁₂ receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. <i>Blood</i> , 2003, 101, 3908-3914.	0.6	199
50	The antiaggregating activity of clopidogrel is not affected by N-acetyl L-cysteine. <i>Thrombosis and Haemostasis</i> , 2003, 90, 839-843.	1.8	3
51	Variable extent of clopidogrel responsiveness in patients after coronary stenting. <i>Thrombosis and Haemostasis</i> , 2004, 92, 1201-1206.	1.8	67
52	Impaired platelet responses to clopidogrel and ticlopidine in a patient with recurrent coronary stent stenosis. <i>Thrombosis and Haemostasis</i> , 2004, 92, 1446-1447.	1.8	4
53	Molecular Recognition at Purine and Pyrimidine Nucleotide (P2) Receptors. <i>Current Topics in Medicinal Chemistry</i> , 2004, 4, 805-819.	1.0	48
54	Expert Consensus Document on the Use of Antiplatelet Agents The Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology. <i>European Heart Journal</i> , 2004, 25, 166-181.	1.0	334

#	ARTICLE	IF	CITATIONS
55	Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 308, 189-197.	1.3	236
56	Absence of Interaction Between Atorvastatin or Other Statins and Clopidogrel. <i>Archives of Internal Medicine</i> , 2004, 164, 2051.	4.3	142
57	Are we making efficient use of clopidogrel?. <i>European Heart Journal</i> , 2004, 25, 454-456.	1.0	11
58	The Value of Clopidogrel versus Aspirin in Reducing Atherothrombotic Events. <i>Pharmacoeconomics</i> , 2004, 22, 19-27.	1.7	27
59	Contribution of Hepatic Cytochrome P450 3A4 Metabolic Activity to the Phenomenon of Clopidogrel Resistance. <i>Circulation</i> , 2004, 109, 166-171.	1.6	449
60	Atorvastatin Does Not Affect the Antiplatelet Potency of Clopidogrel When It Is Administered Concomitantly for 5 Weeks in Patients With Acute Coronary Syndromes. <i>Circulation</i> , 2004, 109, 1335-1338.	1.6	137
61	Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. <i>European Heart Journal</i> , 2004, 25, 1898-1902.	1.0	80
62	Gi-dependent and -independent mechanisms downstream of the P2Y12 ADP-receptor. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 135-146.	1.9	52
63	Identification of the active metabolite of ticlopidine from rat in vitro metabolites. <i>British Journal of Pharmacology</i> , 2004, 142, 551-557.	2.7	60
64	Prodrug research: futile or fertile?. <i>Biochemical Pharmacology</i> , 2004, 68, 2097-2106.	2.0	106
65	Clopidogrel: How good is it and how does it work?. <i>Current Cardiology Reports</i> , 2004, 6, 264-268.	1.3	14
66	Design, synthesis, and inhibition of platelet aggregation for some 1-o-chlorophenyl-1,2,3,4-tetrahydroisoquinoline derivatives. <i>Bioorganic and Medicinal Chemistry</i> , 2004, 12, 6547-6557.	1.4	33
67	Antiplatelet effects and pharmacodynamics of clopidogrel in cats. <i>Journal of the American Veterinary Medical Association</i> , 2004, 225, 1406-1411.	0.2	78
69	The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease. <i>Platelets</i> , 2004, 15, 117-125.	1.1	70
70	Avoidance of Bleeding During Surgery in Patients Receiving Anticoagulant and/or Antiplatelet Therapy. <i>Clinical Pharmacokinetics</i> , 2004, 43, 963-981.	1.6	118
71	Lessons Learned from Marketed and Investigational Prodrugs. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 2393-2404.	2.9	339
72	Functional expression of human and mouse P2Y12 receptors in <i>Saccharomyces cerevisiae</i> . <i>Biochemical and Biophysical Research Communications</i> , 2004, 324, 171-177.	1.0	44
73	Clopidogrel-Statins Interaction. <i>Cardiology in Review</i> , 2004, 12, 236-239.	0.6	3

#	ARTICLE	IF	CITATIONS
74	Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects. <i>Chest</i> , 2004, 126, 234S-264S.	0.4	578
75	The Value of Clopidogrel in Addition to Standard Therapy in Reducing Atherothrombotic Events. <i>Pharmacoeconomics</i> , 2004, 22, 29-41.	1.7	8
76	Clinical Monitoring of the Brain and Spinal Cord. <i>Refresher Courses in Anesthesiology</i> , 2005, 33, 225-234.	0.1	0
77	Hematologic Aspects of Cardiac Surgery. <i>Refresher Courses in Anesthesiology</i> , 2005, 33, 213-223.	0.1	3
78	Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 85-92.	1.9	367
79	Protease-activated receptors in hemostasis, thrombosis and vascular biology. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1800-1814.	1.9	909
80	Not all statins interfere with clopidogrel during antiplatelet therapy. <i>European Journal of Clinical Investigation</i> , 2005, 35, 476-481.	1.7	40
81	Pharmacology of vascular endothelium. <i>FEBS Journal</i> , 2005, 272, 2956-2967.	2.2	14
82	Existence of a Clinically Relevant Interaction between Clopidogrel and HMG-CoA Reductase Inhibitors? Re-evaluating the Evidence. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2005, 96, 103-110.	1.2	14
83	The platelet P2 receptors as molecular targets for old and new antiplatelet drugs. , 2005, 108, 180-192.		96
84	Resistance to antiplatelet therapy. <i>Current Cardiology Reports</i> , 2005, 7, 242-248.	1.3	15
85	A patient with stent thrombosis, clopidogrel-resistance and failure to metabolize clopidogrel to its active metabolite. <i>Thrombosis and Haemostasis</i> , 2005, 93, 789-791.	1.8	26
86	Platelet P2Y12 receptors enhance signalling towards procoagulant activity and thrombin generation. <i>Thrombosis and Haemostasis</i> , 2005, 93, 1128-1136.	1.8	88
87	Clopidogrel inhibits platelet-leukocyte adhesion and plateletdependent leukocyte activation. <i>Thrombosis and Haemostasis</i> , 2005, 94, 568-577.	1.8	115
88	The inhibitory potency of clopidogrel on ADP-induced platelet activation is not attenuated when it is co-administered with atorvastatin (20â€‰mg/day) for 5 weeks in patients with acute coronary syndromes. <i>Platelets</i> , 2005, 16, 287-292.	1.1	17
89	Molecular Regulation of Platelet-Dependent Thrombosis. <i>Circulation</i> , 2005, 112, 2725-2734.	1.6	93
90	Platelet Aggregation and Adenosine Diphosphate/Adenosine Triphosphate Receptors: A Historical Perspective. <i>Seminars in Thrombosis and Hemostasis</i> , 2005, 31, 129-138.	1.5	37
91	The Platelet P2 Receptors in Thrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2005, 31, 162-167.	1.5	53

#	ARTICLE	IF	CITATIONS
92	Clopidogrel and Ticlopidine: P2Y ₁₂ Adenosine Diphosphate-Receptor Antagonists for the Prevention of Atherothrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2005, 31, 174-183.	1.5	302
93	Pharmacology of CS-747 (prasugrel, LY640315), a Novel, Potent Antiplatelet Agent with in Vivo P2Y ₁₂ Receptor Antagonist Activity. <i>Seminars in Thrombosis and Hemostasis</i> , 2005, 31, 184-194.	1.5	241
94	Molecular Recognition at Adenine Nucleotide (P ₂) Receptors in Platelets. <i>Seminars in Thrombosis and Hemostasis</i> , 2005, 31, 205-216.	1.5	16
95	Inhibition of Platelet Activation and Aggregation. <i>Handbook of Experimental Pharmacology</i> , 2005, , 443-462.	0.9	13
96	Enhanced Antiplatelet Effects of Clopidogrel plus Acetylsalicylic Acid Compared with Acetylsalicylic Acid Alone or Combined with Extended-Release Dipyridamole in Healthy Volunteers. <i>Cerebrovascular Diseases</i> , 2005, 19, 214-219.	0.8	6
97	Effect of Clopidogrel Pretreatment Before Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction Treated With Fibrinolytics<SUBTITLE>The PCI-CLARITY Study</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 1224.	3.8	644
98	Association of a Functional Polymorphism in the Clopidogrel Target Receptor Gene, P2Y ₁₂ , and the Risk for Ischemic Cerebrovascular Events in Patients With Peripheral Artery Disease. <i>Stroke</i> , 2005, 36, 1394-1399.	1.0	87
99	Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (Prasugrel, LY640315), a novel P2Y ₁₂ receptor inhibitor. <i>Thrombosis and Haemostasis</i> , 2005, 94, 593-598.	1.8	62
100	Management of the Anticoagulated Patient. <i>Thoracic Surgery Clinics</i> , 2005, 15, 243-262.	0.4	1
101	Absorption, Metabolization, and Antiplatelet Effects of 300-, 600-, and 900-mg Loading Doses of Clopidogrel. <i>Circulation</i> , 2005, 112, 2946-2950.	1.6	605
102	Endothelial action of thienopyridines and thienopyrimidinones in the isolated guinea pig heart. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2005, 72, 139-145.	1.0	46
103	Superior efficacy of clopidogrel plus acetylsalicylic acid compared with extended-release dipyridamole plus acetylsalicylic acid in preventing arterial thrombogenesis in healthy volunteers. <i>Thrombosis Research</i> , 2005, 116, 293-300.	0.8	7
104	Lack of association between the P2Y ₁₂ receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. <i>Thrombosis Research</i> , 2005, 116, 491-497.	0.8	137
105	Evaluation of clopidogrel resistance. <i>Thrombosis Research</i> , 2005, 116, 451-453.	0.8	3
106	Can N-acetylcysteine reverse the antiplatelet effects of clopidogrel? An in vivo and vitro study. <i>American Heart Journal</i> , 2005, 150, 796-799.	1.2	7
108	Association of a Functional Polymorphism in the Clopidogrel Target Receptor Gene P2Y ₁₂ and the Risk for Ischemic Cerebrovascular Events in Patients With Peripheral Arterial Disease. <i>Journal of Vascular Surgery</i> , 2006, 43, 640.	0.6	0
109	Clopidogrel Bisulfate. <i>American Journal of Cardiovascular Drugs</i> , 2006, 6, 407-414.	1.0	11
110	Contribution of Gene Sequence Variations of the Hepatic Cytochrome P450 3A4 Enzyme to Variability in Individual Responsiveness to Clopidogrel. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 1895-1900.	1.1	214

#	ARTICLE	IF	CITATIONS
111	The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 11069-11074.	3.3	278
112	Controversia terapéutica: clopidogrel y estatinas. Clínica E Investigación En Arteriosclerosis, 2006, 18, 34-48.	0.4	0
113	Present and Future Anticoagulants. Advances in Anesthesia, 2006, 24, 29-66.	0.5	4
114	Antiplatelet Agents Aspirin and Clopidogrel Are Hydrolyzed by Distinct Carboxylesterases, and Clopidogrel Is Transesterificated in the Presence of Ethyl Alcohol. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 1467-1476.	1.3	225
115	The platelet P2 receptors in arterial thrombosis. Blood Cells, Molecules, and Diseases, 2006, 36, 223-227.	0.6	43
116	The role of ADP receptors in platelet function. Frontiers in Bioscience - Landmark, 2006, 11, 1977.	3.0	152
118	Pharmacology of thienopyridines: rationale for dual pathway inhibition. Country Review Ukraine, 2006, 8, G3-G9.	0.8	20
119	Clopidogrel resistance caused by a failure to metabolize clopidogrel into its metabolites. Journal of Thrombosis and Haemostasis, 2006, 4, 1143-1145.	1.9	24
120	Role of the P2Y12 gene polymorphism in platelet responsiveness to clopidogrel in healthy subjects. Journal of Thrombosis and Haemostasis, 2006, 4, 2096-2097.	1.9	36
121	Antiplatelet Drug Resistance and Drug-Drug Interactions: Role of Cytochrome P450 3A4. Pharmaceutical Research, 2006, 23, 2691-2708.	1.7	41
122	Clopidogrel reduces the development of transplant arteriosclerosis. Journal of Thoracic and Cardiovascular Surgery, 2006, 131, 1161-1166.	0.4	43
123	Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. , 2006, 110, 415-432.		476
124	Combination of Clopidogrel and Statins: A Hypothetical Interaction or Therapeutic Dilemma?. Pharmacotherapy, 2006, 26, 388-394.	1.2	11
125	Clopidogrel in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention. Expert Opinion on Pharmacotherapy, 2006, 7, 1669-1673.	0.9	0
126	Antithrombotic Therapy. Current Molecular Medicine, 2006, 6, 603-619.	0.6	9
127	The Platelet ATP and ADP Receptors. Current Pharmaceutical Design, 2006, 12, 859-875.	0.9	56
128	Biology and Pharmacology of the Platelet P2Y12 Receptor. Current Pharmaceutical Design, 2006, 12, 1255-1259.	0.9	165
129	Thienopyridines and Statins: Assessing a Potential Drug-Drug Interaction. Current Pharmaceutical Design, 2006, 12, 1271-1280.	0.9	27

#	ARTICLE	IF	CITATIONS
130	Clopidogrel Resistance: Implications for Coronary Stenting. <i>Current Pharmaceutical Design</i> , 2006, 12, 1261-1269.	0.9	20
131	Clopidogrel resistance: fact and fiction. <i>Future Cardiology</i> , 2006, 2, 215-228.	0.5	19
132	Chemical toxicology: reactive intermediates and their role in pharmacology and toxicology. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2006, 2, 923-946.	1.5	67
133	Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy. <i>Platelets</i> , 2006, 17, 250-258.	1.1	65
134	REGULATION OF PLATELET FUNCTIONS BY P2 RECEPTORS. <i>Annual Review of Pharmacology and Toxicology</i> , 2006, 46, 277-300.	4.2	245
135	International Union of Pharmacology LVIII: Update on the P2Y G Protein-Coupled Nucleotide Receptors: From Molecular Mechanisms and Pathophysiology to Therapy. <i>Pharmacological Reviews</i> , 2006, 58, 281-341.	7.1	1,147
136	INTERACTIONS OF TWO MAJOR METABOLITES OF PRASUGREL, A THIENOPYRIDINE ANTIPLATELET AGENT, WITH THE CYTOCHROMES P450. <i>Drug Metabolism and Disposition</i> , 2006, 34, 600-607.	1.7	262
137	Clopidogrel: a pharmacoeconomic review. <i>Journal of Medical Economics</i> , 2007, 10, 553-571.	1.0	0
138	Absorption, distribution and excretion of the new thienopyridine agent prasugrel in rats. <i>Xenobiotica</i> , 2007, 37, 788-801.	0.5	12
139	Significance of Aspirin and Clopidogrel Resistance in Patients Undergoing Percutaneous Coronary Interventions. <i>Current Vascular Pharmacology</i> , 2007, 5, 135-140.	0.8	2
140	Drug evaluation of clopidogrel in patients with ischemic stroke. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2825-2838.	0.9	8
141	Statins Increase Risk of Hemorrhagic Stroke by Inhibition of the PAR-1 Receptor. <i>Cerebrovascular Diseases</i> , 2007, 24, 477-479.	0.8	15
142	Interleukin-6 Alters the Cellular Responsiveness to Clopidogrel, Irinotecan, and Oseltamivir by Suppressing the Expression of Carboxylesterases HCE1 and HCE2. <i>Molecular Pharmacology</i> , 2007, 72, 686-694.	1.0	75
143	Increased Active Metabolite Formation Explains the Greater Platelet Inhibition With Prasugrel Compared to High-dose Clopidogrel. <i>Journal of Cardiovascular Pharmacology</i> , 2007, 50, 555-562.	0.8	159
144	Whole blood aggregometry for evaluation of the antiplatelet effects of clopidogrel. <i>Thrombosis Research</i> , 2007, 119, 285-291.	0.8	27
145	Effect of clopidogrel on the inflammatory progression of early atherosclerosis in rabbits model. <i>Atherosclerosis</i> , 2007, 194, 348-356.	0.4	51
146	Medical Treatment of Stable Angina. , 2007, , 911-936.		0
147	Platelet Inhibitors and Monitoring Platelet Function: Implications for Bleeding. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 51-63.	0.9	5

#	ARTICLE	IF	CITATIONS
148	Thiosulfonates modulate platelet activation by reaction with surface free sulfhydryls and internal thiol-containing proteins. <i>Platelets</i> , 2007, 18, 481-490.	1.1	9
149	Clopidogrel. <i>Drugs</i> , 2007, 67, 613-646.	4.9	67
150	Pharmacologic Options for Treatment of Ischemic Disease. , 2007, , 77-120.		4
151	The Platelet P2 Receptors. , 2007, , 201-220.		14
152	Thienopyridines in cardiovascular disease: Focus on Clopidogrel resistance. <i>Thrombosis and Haemostasis</i> , 2007, 97, 385-393.	1.8	95
153	ADP Receptor Antagonists. , 2007, , 1127-1144.		13
154	A novel P2Y12 adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog models. <i>Thrombosis and Haemostasis</i> , 2007, 97, 847-855.	1.8	39
155	Therapeutic Inhibitors of Platelet Aggregation – from Aspirin to Integrin Blockers. <i>Transfusion Medicine and Hemotherapy</i> , 2007, 34, 44-54.	0.7	10
158	Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 735-741.	2.3	295
159	Optimizing Platelet P2Y12 Inhibition for Patients Undergoing PCI. <i>Cardiovascular Drug Reviews</i> , 2007, 25, 188-203.	4.4	29
160	Prasugrel: A Novel Thienopyridine Antiplatelet Agent. A Review of Preclinical and Clinical Studies and the Mechanistic Basis for Its Distinct Antiplatelet Profile. <i>Cardiovascular Drug Reviews</i> , 2007, 25, 357-374.	4.4	227
161	Ticlopidine could be an alternative therapy in the case of pharmacological resistance to clopidogrel: a report of three cases. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 879-881.	1.9	18
162	The flow cytometric VASP assay can be used to determine the effectiveness of clopidogrel in patients treated with abciximab. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 881-883.	1.9	16
163	The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 1545-1551.	1.9	206
164	Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 2429-2436.	1.9	668
165	The genetics of aspirin resistance. <i>International Journal of Clinical Practice</i> , 2007, 61, 826-834.	0.8	47
166	Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. <i>Lancet Neurology</i> , The, 2007, 6, 961-969.	4.9	495
167	Is there a role for combinations of antiplatelet agents in stroke prevention?. <i>Current Treatment Options in Neurology</i> , 2007, 9, 442-450.	0.7	1

#	ARTICLE	IF	CITATIONS
168	The Antiplatelet Effect of Higher Loading and Maintenance Dose Regimens of Clopidogrel. <i>JACC: Cardiovascular Interventions</i> , 2008, 1, 612-619.	1.1	52
169	Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2008, 35, 593-618.	0.8	50
171	Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 589-597.	0.8	41
172	Use of antiplatelet agents to prevent stroke: What is the role for combinations of medications?. <i>Current Neurology and Neuroscience Reports</i> , 2008, 8, 29-34.	2.0	5
173	Relationships between optical aggregometry (type born) and flow cytometry in evaluating ADP-induced platelet activation. <i>Cytometry Part B - Clinical Cytometry</i> , 2008, 74B, 30-39.	0.7	25
174	Quantitative determination of clopidogrel active metabolite in human plasma by LC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2008, 48, 1219-1224.	1.4	111
175	Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement. <i>Thrombosis and Haemostasis</i> , 2008, 99, 174-181.	1.8	52
176	The Effect of CYP2C19 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Clopidogrel: A Possible Mechanism for Clopidogrel Resistance. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 84, 236-242.	2.3	270
177	Pharmacokinetics of clopidogrel in patients with stent thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1230-1232.	1.9	11
178	The reversible P2Y ₁₂ antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1153-1159.	1.9	91
179	The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1439-1441.	1.9	142
180	Interaction of the active metabolite of prasugrel, R-138727, with cysteine ⁹⁷ and cysteine ¹⁷⁵ of the human P2Y ₁₂ receptor. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1908-1914.	1.9	88
181	P2 receptors, platelet function and pharmacological implications. <i>Thrombosis and Haemostasis</i> , 2008, 99, 466-472.	1.8	250
182	Lipophilic Modifications to Dinucleoside Polyphosphates and Nucleotides that Confer Antagonist Properties at the Platelet P2Y ₁₂ Receptor. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 1007-1025.	2.9	37
183	Cytochrome P450 2C19 681G>A Polymorphism and High On-Clopidogrel Platelet Reactivity Associated With Adverse 1-Year Clinical Outcome of Elective Percutaneous Coronary Intervention With Drug-Eluting or Bare-Metal Stents. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1925-1934.	1.2	523
184	Will Measuring Vasodilator-Stimulated Phosphoprotein Phosphorylation Help Us Optimize the Loading Dose of Clopidogrel? Editorials published in the <i>Journal of the American College of Cardiology</i> reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1412-1414.	1.2	10
185	Calcium-Channel Blockers Reduce the Antiplatelet Effect of Clopidogrel. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1557-1563.	1.2	240
186	Clopidogrel and Calcium-Channel Antagonists. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1564-1566.	1.2	7

#	ARTICLE	IF	CITATIONS
187	Successful Treatment of Rotary Pump Thrombus With the Glycoprotein IIb/IIIa Inhibitor Tirofiban. <i>Journal of Heart and Lung Transplantation</i> , 2008, 27, 925-927.	0.3	53
188	Antiplatelet drug nonresponsiveness. <i>American Heart Journal</i> , 2008, 155, 591-599.	1.2	52
189	Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (I): In vitro effects on platelets. <i>Thrombosis Research</i> , 2008, 122, 523-532.	0.8	27
190	Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. <i>European Heart Journal</i> , 2008, 30, 916-922.	1.0	353
191	Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: A potential antiplatelet therapeutic target. <i>Platelets</i> , 2008, 19, 595-604.	1.1	101
192	Chapter 64 Antithrombotic agents for stroke prevention. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2008, 94, 1277-1294.	1.0	2
193	The use of the Verify <i>Now</i> system to monitor antiplatelet therapy: A review of the current evidence. <i>Platelets</i> , 2008, 19, 479-488.	1.1	106
195	Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 766-780.	3.3	80
196	Designing Prodrugs and Bioprecursors. , 2008, , 721-746.		12
197	Antiplatelet Drugs. <i>Chest</i> , 2008, 133, 199S-233S.	0.4	478
198	Comparison of Human Cytochrome P450 Inhibition by the Thienopyridines Prasugrel, Clopidogrel, and Ticlopidine. <i>Drug Metabolism and Pharmacokinetics</i> , 2008, 23, 412-420.	1.1	70
199	CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. <i>Pharmacogenomics</i> , 2008, 9, 1251-1259.	0.6	209
200	Resistance to Aspirin and Thienopyridines in Diabetes Mellitus and Metabolic Syndrome. <i>Current Vascular Pharmacology</i> , 2008, 6, 313-328.	0.8	30
201	Prasugrel. <i>Cardiology in Review</i> , 2008, 16, 314-318.	0.6	16
202	A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry. <i>Thrombosis and Haemostasis</i> , 2008, 99, 215-222.	1.8	73
203	Multiple electrode aggregometry and P2Y12 antagonists. <i>Thrombosis and Haemostasis</i> , 2008, 99, 1127-1129.	1.8	39
204	Prodrugs in Cardiovascular Therapy. <i>Molecules</i> , 2008, 13, 1156-1178.	1.7	7
205	How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification. <i>Thrombosis and Haemostasis</i> , 2008, 99, 357-362.	1.8	52

#	ARTICLE	IF	CITATIONS
206	Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel. <i>Vascular Health and Risk Management</i> , 2009, 5, 475.	1.0	5
207	Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. <i>Vascular Health and Risk Management</i> , 2009, 5, 873.	1.0	37
208	Review of Prasugrel for the Secondary Prevention of Atherothrombosis. <i>Journal of Managed Care Pharmacy</i> , 2009, 15, 383-395.	2.2	20
209	Interaction of New, Very Potent Non-Nucleotide Antagonists with Arg256 of the Human Platelet P2Y ₁₂ Receptor. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 331, 648-655.	1.3	59
210	A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. <i>Cmaj</i> , 2009, 180, 713-718.	0.9	622
211	Cytochrome P-450 Polymorphisms and Response to Clopidogrel. <i>New England Journal of Medicine</i> , 2009, 360, 2249-2251.	13.9	25
212	Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development. <i>Current Medicinal Chemistry</i> , 2009, 16, 4066-4218.	1.2	107
213	Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development. <i>Current Medicinal Chemistry</i> , 2009, 16, 3480-3675.	1.2	142
214	The drug-drug interaction between proton pump inhibitors and clopidogrel. <i>Cmaj</i> , 2009, 180, 699-700.	0.9	43
215	Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. <i>Thrombosis and Haemostasis</i> , 2009, 101, 714-719.	1.8	343
216	Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 849.	3.8	1,319
217	Pharmacokinetics and Pharmacodynamics of Prasugrel, a Thienopyridine P2Y ₁₂ Inhibitor. <i>Pharmacotherapy</i> , 2009, 29, 1089-1102.	1.2	78
218	Advances in Antiplatelet Therapy: Agents in Clinical Development. <i>American Journal of Cardiology</i> , 2009, 103, 40A-51A.	0.7	88
219	The Biochemistry of Drug Metabolism - An Introduction. <i>Chemistry and Biodiversity</i> , 2009, 6, 591-684.	1.0	58
220	Drug Metabolism for the Perplexed Medicinal Chemist. <i>Chemistry and Biodiversity</i> , 2009, 6, 2055-2070.	1.0	30
221	Prodrug Approaches for Enhancing the Bioavailability of Drugs with Low Solubility. <i>Chemistry and Biodiversity</i> , 2009, 6, 2071-2083.	1.0	110
222	Comparing the antiplatelet effect of clopidogrel hydrogensulfate and clopidogrel besylate: a crossover study. <i>Clinical Research in Cardiology</i> , 2009, 98, 533-540.	1.5	36
223	Separation and determination of clopidogrel and its impurities by capillary electrophoresis. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2009, 49, 193-200.	1.4	45

#	ARTICLE	IF	CITATIONS
224	Beyond platelet inhibition: potential pleiotropic effects of ADP-receptor antagonists. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 27, 300-306.	1.0	5
225	Effects of rosuvastatin on platelet inhibition by clopidogrel in cardiovascular patients. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 28, 151-155.	1.0	14
226	Development of selective agonists and antagonists of P2Y receptors. <i>Purinergic Signalling</i> , 2009, 5, 75-89.	1.1	101
227	Genetic CYP2C19 polymorphism dependent non-responders to clopidogrel therapy – Does structural design, dosing and induction strategies have a role to play?. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2009, 34, 147-150.	0.6	4
229	Studies on the role of the extracellular cysteines and oligomeric structures of the P2Y12 receptor when interacting with antagonists. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 232-234.	1.9	36
230	6-Amino-2-mercapto-3H-pyrimidin-4-one derivatives as new candidates for the antagonism at the P2Y12 receptors. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 4612-4621.	1.4	39
231	Piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 4657-4663.	1.0	24
232	Thienopyrimidine-based P2Y12 platelet aggregation inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 5919-5923.	1.0	23
233	Piperazinyl-glutamate-pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 6148-6156.	1.0	18
234	Cangrelor increases the magnitude of platelet inhibition and reduces interindividual variability in clopidogrel-pretreated subjects. <i>Netherlands Heart Journal</i> , 2009, 17, 195-198.	0.3	10
235	Drug-Drug Interaction Between Clopidogrel and the Proton Pump Inhibitors. <i>Annals of Pharmacotherapy</i> , 2009, 43, 1266-1274.	0.9	101
236	Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. <i>American Heart Journal</i> , 2009, 157, 148.e1-148.e5.	1.2	313
237	Facts and controversies of aspirin and clopidogrel therapy. <i>American Heart Journal</i> , 2009, 157, 412-422.	1.2	20
238	Polymorphism of human cytochrome P450 enzymes and its clinical impact. <i>Drug Metabolism Reviews</i> , 2009, 41, 89-295.	1.5	671
239	Sirolimus and Everolimus Induce Endothelial Cellular Senescence Via Sirtuin 1 Down-Regulation. <i>Journal of the American College of Cardiology</i> , 2009, 53, 2298-2305.	1.2	74
240	Measurement of platelet P-selectin for remote testing of platelet function during treatment with clopidogrel and/or aspirin. <i>Platelets</i> , 2009, 20, 250-259.	1.1	42
241	Clopidogrel Resistance: Pharmacokinetic or Pharmacogenetic?. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 506-512.	1.0	39
242	Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. <i>European Heart Journal</i> , 2009, 30, 1744-1752.	1.0	231

#	ARTICLE	IF	CITATIONS
243	ADME pharmacogenetics: current practices and future outlook. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 449-462.	1.5	25
244	Covalent Modifiers: An Orthogonal Approach to Drug Design. Journal of Medicinal Chemistry, 2009, 52, 1231-1246.	2.9	299
245	Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet, The, 2009, 373, 309-317.	6.3	864
246	Clopidogrel in acute coronary syndrome: to genotype or not?. Lancet, The, 2009, 373, 276-278.	6.3	24
247	Cytochrome P450 2C19 polymorphism and clopidogrel after MI. Lancet, The, 2009, 373, 1171-1172.	6.3	5
248	High-Affinity, Non-Nucleotide-Derived Competitive Antagonists of Platelet P2Y ₁₂ Receptors. Journal of Medicinal Chemistry, 2009, 52, 3784-3793.	2.9	89
249	Recent developments in clopidogrel pharmacology and their relation to clinical outcomes. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 989-1004.	1.5	70
250	Attenuation of Transplant Arteriosclerosis With Clopidogrel Is Associated With a Reduction of Infiltrating Dendritic Cells and Macrophages in Murine Aortic Allografts. Transplantation, 2009, 87, 207-216.	0.5	39
251	Updates on Cytochrome P450-Mediated Cardiovascular Drug Interactions. American Journal of Therapeutics, 2009, 16, 155-163.	0.5	17
252	In Vivo Metabolite Kinetics. , 0, , 41-64.		3
253	Functional variability of platelet response to clopidogrel correlates with P2Y ₁₂ receptor occupancy. Thrombosis and Haemostasis, 2009, 101, 116-122.	1.8	25
254	Interaction Between Clopidogrel and Proton Pump Inhibitors: Hypothesis to Explain Multifactorial CYP2C19 Inhibition. Drug Metabolism Letters, 2009, 3, 287-289.	0.5	12
255	Targeting Platelet G-Protein Coupled Receptors (GPCRs): Looking Beyond Conventional GPCR Antagonism. Current Vascular Pharmacology, 2010, 8, 140-154.	0.8	19
256	Genetic predisposition to adverse drug reactions in the intensive care unit. Critical Care Medicine, 2010, 38, S106-S116.	0.4	52
257	Pantoprazole Does Not Influence the Antiplatelet Effect of Clopidogrel-A Whole Blood Aggregometry Study After Coronary Stenting. Journal of Cardiovascular Pharmacology, 2010, 56, 91-97.	0.8	48
258	Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation. Pharmacogenetics and Genomics, 2010, 20, 18-25.	0.7	81
259	Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation. Thrombosis and Haemostasis, 2010, 104, 1211-1218.	1.8	41
260	Clopidogrel pathway. Pharmacogenetics and Genomics, 2010, 20, 463-465.	0.7	184

#	ARTICLE	IF	CITATIONS
261	Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics: A foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies. <i>Thrombosis and Haemostasis</i> , 2010, 103, 535-544.	1.8	39
262	Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors. <i>Thrombosis and Haemostasis</i> , 2010, 104, 626-632.	1.8	28
263	Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition. <i>Heart</i> , 2010, 96, 186-189.	1.2	106
264	Metabolism and Disposition of the Thienopyridine Antiplatelet Drugs Ticlopidine, Clopidogrel, and Prasugrel in Humans. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 126-142.	1.0	345
265	Factors associated with clopidogrel nonresponsiveness. <i>Future Cardiology</i> , 2010, 6, 195-210.	0.5	10
266	Development and validation of high-throughput liquid chromatography-tandem mass spectrometric method for simultaneous quantification of Clopidogrel and its metabolite in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 502-508.	1.2	16
267	Capillary Zone Electrophoresis method for determination of (+)-S clopidogrel carboxylic acid metabolite in human plasma and urine designed for biopharmaceutical studies. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 1013-1018.	1.2	13
268	Simultaneous determination of clopidogrel and its carboxylic acid metabolite by capillary electrophoresis. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 1480-1486.	1.2	13
269	Risk of Adverse Clinical Outcomes with Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Percutaneous Coronary Intervention. <i>Digestive Diseases and Sciences</i> , 2010, 55, 1964-1968.	1.1	66
270	Development and validation of an HPLC-MS/MS method to determine clopidogrel in human plasma. Use of incurred samples to test back-conversion. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 3134-3142.	1.2	35
271	Part II: Piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 1388-1394.	1.0	14
272	Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 482-488.	1.9	95
273	Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel <i>in vitro</i> . <i>British Journal of Pharmacology</i> , 2010, 161, 393-404.	2.7	43
274	Chemoselective small molecules that covalently modify one lysine in a non-enzyme protein in plasma. <i>Nature Chemical Biology</i> , 2010, 6, 133-139.	3.9	74
275	Synthesis of alkyl- and aryl-amino-substituted anthraquinone derivatives by microwave-assisted copper(0)-catalyzed Ullmann coupling reactions. <i>Nature Protocols</i> , 2010, 5, 945-953.	5.5	52
276	Combination of clopidogrel and everolimus dramatically reduced the development of transplant arteriosclerosis in murine aortic allografts. <i>Transplant International</i> , 2010, 23, 959-66.	0.8	23
277	Reliability of reactive metabolite and covalent binding assessments in prediction of idiosyncratic drug toxicity. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 102-123.		1
278	Antiplatelet agents and proton pump inhibitors – personalizing treatment. <i>Pharmacogenomics and Personalized Medicine</i> , 2010, 3, 101.	0.4	1

#	ARTICLE	IF	CITATIONS
279	Ausência de interação clopidogrel-estatina em pacientes submetidos a implante de "stent" coronário. Arquivos Brasileiros De Cardiologia, 2010, 95, 321-327.	0.3	4
280	The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thrombosis and Haemostasis, 2010, 103, 920-925.	1.8	80
281	Problems of contemporary antiplatelet treatment. Postępy W Kardiologii Interwencyjnej, 2010, 1, 21-29.	0.1	0
282	Review Article: Combination of Clopidogrel and Proton Pump Inhibitors: Implications for Clinicians. Journal of Cardiovascular Pharmacology and Therapeutics, 2010, 15, 326-337.	1.0	18
284	Implementing genotype-guided antithrombotic therapy. Future Cardiology, 2010, 6, 409-424.	0.5	22
285	CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. European Heart Journal, 2010, 31, 3046-3053.	1.0	138
286	Pharmacodynamic and pharmacokinetic evaluation of clopidogrel and the carboxylic acid metabolite SR 26334 in healthy dogs. American Journal of Veterinary Research, 2010, 71, 822-830.	0.3	62
287	Pharmacogenetics guided anticoagulation. Clinical Chemistry and Laboratory Medicine, 2010, 48, S119-27.	1.4	0
288	Platelet function tests for the monitoring of P2Y12 inhibitors. Expert Opinion on Medical Diagnostics, 2010, 4, 251-265.	1.6	2
289	Nonresponders to clopidogrel: pharmacokinetics and interactions involved. Expert Opinion on Pharmacotherapy, 2010, 11, 2391-2403.	0.9	13
290	Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. European Heart Journal, 2010, 31, 1205-1211.	1.0	75
291	Impact of Cytochrome P450 2C19 Loss-of-Function Polymorphism and of Major Demographic Characteristics on Residual Platelet Function After Loading and Maintenance Treatment With Clopidogrel in Patients Undergoing Elective Coronary Stent Placement. Journal of the American College of Cardiology, 2010, 55, 2427-2434.	1.2	285
292	The H2-receptor antagonist ranitidine interferes with clopidogrel-mediated P2Y12 inhibition in platelets. Pharmacological Research, 2010, 62, 352-356.	3.1	8
293	Drug-Drug Interaction Profiles of Proton Pump Inhibitors. Clinical Pharmacokinetics, 2010, 49, 509-533.	1.6	144
294	Piperazinyl Glutamate Pyridines as Potent Orally Bioavailable P2Y ₁₂ Antagonists for Inhibition of Platelet Aggregation. Journal of Medicinal Chemistry, 2010, 53, 2010-2037.	2.9	41
295	Updates on Cytochrome P450-Mediated Cardiovascular Drug Interactions. Disease-a-Month, 2010, 56, 163-179.	0.4	10
296	Rationale and design of the randomized, double-blind trial testing Intravenous and Oral administration of elinogrel, a selective and reversible P2Y12-receptor inhibitor, versus clopidogrel to evaluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). American Heart Journal, 2010, 160, 65-72.	1.2	72
297	Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement. Circulation, 2010, 121, 512-518.	1.6	514

#	ARTICLE	IF	CITATIONS
298	Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment. <i>Thrombosis and Haemostasis</i> , 2010, 104, 1193-1200.	1.8	68
299	Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite. <i>Drug Metabolism and Disposition</i> , 2010, 38, 92-99.	1.7	711
300	Proton Pump Inhibitors and Clopidogrel. <i>Cardiovascular Therapeutics</i> , 2010, 28, 169-176.	1.1	2
301	Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. <i>Lancet, The</i> , 2010, 376, 1320-1328.	6.3	709
303	Strategies for discovering and derisking covalent, irreversible enzyme inhibitors. <i>Future Medicinal Chemistry</i> , 2010, 2, 949-964.	1.1	319
305	Emerging drugs for acute myocardial infarction. <i>Expert Opinion on Emerging Drugs</i> , 2010, 15, 87-105.	1.0	1
306	Comparative Effectiveness Research and Personalized Medicine. <i>Pharmacoeconomics</i> , 2010, 28, 905-913.	1.7	40
307	The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 999-1014.	0.6	4
308	Calcium-Channel Blockers Do Not Alter the Clinical Efficacy of Clopidogrel After Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2011, 57, 409-417.	1.2	43
309	Genetic Polymorphisms and the Impact of a Higher Clopidogrel Dose Regimen on Active Metabolite Exposure and Antiplatelet Response in Healthy Subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 287-295.	2.3	77
310	Mode of action of P2Y12 antagonists as inhibitors of platelet function. <i>Thrombosis and Haemostasis</i> , 2011, 105, 96-106.	1.8	24
312	Identification of an antithrombotic allosteric modulator that acts through helix 8 of PAR1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 2951-2956.	3.3	56
314	Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting. <i>American Heart Journal</i> , 2011, 161, 605-610.	1.2	28
315	Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy. <i>American Heart Journal</i> , 2011, 162, 518-526.e5.	1.2	48
316	The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines. <i>Canadian Journal of Cardiology</i> , 2011, 27, S1-S59.	0.8	106
317	P2Y ₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP. <i>Platelets</i> , 2011, 22, 504-515.	1.1	28
318	Focused Clinical Review: Periprocedural Management of Antiplatelet Therapy in Patients with Coronary Stents. <i>Heart Lung and Circulation</i> , 2011, 20, 438-445.	0.2	8
319	Clopidogrel pretreatment in PCI: Absolute requirement or obsolete myth?. <i>International Journal of Cardiology</i> , 2011, 146, 305-310.	0.8	3

#	ARTICLE	IF	CITATIONS
320	An improved method for specific and quantitative determination of the clopidogrel active metabolite isomers in human plasma. <i>Thrombosis and Haemostasis</i> , 2011, 105, 696-705.	1.8	79
321	Pharmacogenomics of clopidogrel: Evidence and perspectives. <i>Thrombosis Research</i> , 2011, 128, 307-316.	0.8	76
322	d-Isomer of gly-tyr-pro-cys-pro-his-pro peptide: A novel and sensitive in vitro trapping agent to detect reactive metabolites by electrospray mass spectrometry. <i>Toxicology in Vitro</i> , 2011, 25, 411-425.	1.1	18
323	Lipopolysaccharide down-regulates carboxylesterases 1 and 2 and reduces hydrolysis activity in vitro and in vivo via p38MAPK/NF- κ B pathway. <i>Toxicology Letters</i> , 2011, 201, 213-220.	0.4	23
324	Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy. <i>Thrombosis and Haemostasis</i> , 2011, 105, 933-944.	1.8	39
325	Combined 3D-QSAR, Molecular Docking, and Molecular Dynamics Study on Piperazinyl-Glutamate-Pyridines/Pyrimidines as Potent P2Y12 Antagonists for Inhibition of Platelet Aggregation. <i>Journal of Chemical Information and Modeling</i> , 2011, 51, 2560-2572.	2.5	38
326	Platelet function variability and non-genetic causes. <i>Thrombosis and Haemostasis</i> , 2011, 105, S60-S66.	1.8	30
327	Clopidogrel withdrawal: Is there a "rebound" phenomenon?. <i>Thrombosis and Haemostasis</i> , 2011, 105, 211-220.	1.8	55
328	Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate. <i>Thrombosis and Haemostasis</i> , 2011, 105, S67-S74.	1.8	28
329	Early determination of clopidogrel responsiveness by platelet reactivity index identifies patients at risk for cardiovascular events after myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2011, 106, 141-148.	1.8	15
330	Antiplatelet Resistance and Thromboembolic Complications in Neurointerventional Procedures. <i>Frontiers in Neurology</i> , 2011, 2, 83.	1.1	31
331	Effect of Atorvastatin and Clopidogrel Co-Administration After Coronary Stenting in Korean Patients With Stable Angina. <i>Korean Circulation Journal</i> , 2011, 41, 28.	0.7	4
332	Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 396-404.	0.8	37
333	The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects. <i>Blood</i> , 2011, 117, 2102-2112.	0.6	162
335	Inhibitory Interaction Between Calcium Channel Blocker and Clopidogrel - Efficacy of Cilostazol to Overcome It -. <i>Circulation Journal</i> , 2011, 75, 2581-2589.	0.7	17
336	Antiplatelet therapy: ADP receptor antagonists. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 647-657.	1.1	87
337	The resurgence of covalent drugs. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 307-317.	21.5	1,384
338	Individual variability in the disposition of and response to clopidogrel: Pharmacogenomics and beyond. , 2011, 129, 267-289.		52

#	ARTICLE	IF	CITATIONS
339	<i>CYP2C19</i> But Not <i>PON1</i> Genetic Variants Influence Clopidogrel Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy in Post-Myocardial Infarction Patients. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 422-428.	1.4	110
340	Antiplatelet agents for the treatment and prevention of atherothrombosis. <i>European Heart Journal</i> , 2011, 32, 2922-2932.	1.0	203
341	Structural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States. <i>Chemical Research in Toxicology</i> , 2011, 24, 1345-1410.	1.7	569
342	Pharmacochemistry of the platelet purinergic receptors. <i>Purinergic Signalling</i> , 2011, 7, 305-324.	1.1	44
343	Molecular defects of the platelet P2 receptors. <i>Purinergic Signalling</i> , 2011, 7, 333-339.	1.1	20
344	Historical perspective on ADP-induced platelet activation. <i>Purinergic Signalling</i> , 2011, 7, 283-292.	1.1	21
345	The P2Y12 receptor as a target of antithrombotic drugs. <i>Purinergic Signalling</i> , 2011, 7, 325-332.	1.1	14
346	P2 receptors and platelet function. <i>Purinergic Signalling</i> , 2011, 7, 293-303.	1.1	108
347	Development and validation of an HPLC-MS/MS method to quantify clopidogrel acyl glucuronide, clopidogrel acid metabolite, and clopidogrel in plasma samples avoiding analyte back-conversion. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 401, 1023-1034.	1.9	48
348	A novel series of piperazinyl-pyridine ureas as antagonists of the purinergic P2Y12 receptor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 2877-2881.	1.0	26
349	The Role of the Cytochrome P450 Polymorphisms in Clopidogrel Efficacy and Clinical Utility. <i>Current Medicinal Chemistry</i> , 2011, 18, 427-438.	1.2	15
350	Role of Platelet Function Testing in Clinical Practice: Current Concepts and Future Perspectives. <i>Current Drug Targets</i> , 2011, 12, 1836-1847.	1.0	11
351	Clinical Herbal Interactions with Conventional Drugs: From Molecules to Maladies. <i>Current Medicinal Chemistry</i> , 2011, 18, 4836-4850.	1.2	95
352	Mechanism-Based Inactivation of Human Cytochrome P450 2B6 by Clopidogrel: Involvement of Both Covalent Modification of Cysteinyln Residue 475 and Loss of Heme. <i>Molecular Pharmacology</i> , 2011, 80, 839-847.	1.0	36
353	Thienopyridines, but Not Elinogrel, Result in Off-Target Effects at the Vessel Wall That Contribute to Bleeding. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 338, 22-30.	1.3	27
354	Body weight: a risk factor for subtherapeutic antithrombotic therapy in neurovascular stenting. <i>Journal of NeuroInterventional Surgery</i> , 2011, 3, 177-181.	2.0	31
355	A Review of the Management of Gastric Acid-Related Diseases: Focus on Rabeprazole. <i>Clinical Medicine Gastroenterology</i> , 2011, 4, CGast.S5133.	0.2	1
356	Metabolic activation of clopidogrel: <i>in vitro</i> data provide conflicting evidence for the contributions of CYP2C19 and PON1. <i>Therapeutic Advances in Drug Safety</i> , 2011, 2, 253-261.	1.0	19

#	ARTICLE	IF	CITATIONS
357	A Clopidogrel-Insensitive Inducible Pool of P2Y ₁₂ Receptors Contributes to Thrombus Formation: Inhibition by Elinogrel, a Direct-Acting, Reversible P2Y ₁₂ Antagonist. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 339, 54-61.	1.3	28
358	The Safety of Proton Pump Inhibitors and Clopidogrel in Patients After Stroke. <i>Stroke</i> , 2011, 42, 128-132.	1.0	27
359	Genomics and Drug Response. <i>New England Journal of Medicine</i> , 2011, 364, 1144-1153.	13.9	552
360	Dissecting the Activation of Thienopyridines by Cytochromes P450 Using a Pharmacodynamic Assay In Vitro. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 339, 589-596.	1.3	17
361	Update on selecting and adjusting antiplatelet therapy for prevention of noncardiogenic, recurrent ischemic stroke. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 1295-1303.	0.6	0
362	Clopidogrel hydrogen sulphate for atrial fibrillation. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1781-1787.	0.9	4
363	Impact of proton pump inhibitors on efficacy of clopidogrel: Review of evidence. <i>Indian Journal of Pharmacology</i> , 2011, 43, 183.	0.4	12
364	Advances in antiplatelet therapy for acute coronary syndromes: Table 1. <i>Postgraduate Medical Journal</i> , 2012, 88, 391-396.	0.9	6
365	Is There a Clinically Significant Interaction Between Calcium Channel Antagonists and Clopidogrel?. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 77-81.	1.4	30
366	Different effects of proton pump inhibitors and famotidine on the clopidogrel metabolic activation by recombinant CYP2B6, CYP2C19 and CYP3A4. <i>Xenobiotica</i> , 2012, 42, 633-640.	0.5	21
367	Platelet Function Profile Post-Clopidogrel Therapy in Patients With Type 2 Diabetes Undergoing Coronary Stent Implantation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2012, 18, 249-257.	0.7	2
368	Clinical Use of Clopidogrel. <i>Current Pharmaceutical Design</i> , 2012, 18, 5224-5239.	0.9	28
369	Anti-Inflammatory Effects of Anti-Platelet Treatment in Atherosclerosis. <i>Current Pharmaceutical Design</i> , 2012, 18, 4311-4325.	0.9	17
370	Clopidogrel Pharmacodynamics and Pharmacokinetics in the Fed and Fasted State: A Randomized Crossover Study of Healthy Men. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1506-1515.	1.0	13
373	Newer agents in antiplatelet therapy: a review. <i>Journal of Blood Medicine</i> , 2012, 3, 33.	0.7	42
374	A Critical Appraisal of the Functional Evolution of P2Y ₁₂ Antagonists as Antiplatelet Drugs. <i>Current Pharmaceutical Design</i> , 2012, 18, 1625-1634.	0.9	1
375	Pharmacogenetics of Clopidogrel. <i>Current Pharmaceutical Design</i> , 2012, 18, 5309-5327.	0.9	16
376	EFFECTS OF DIFFERENT DOSES OF NAOXINTONG COMBINED WITH DUAL ANTIPLATELET THERAPY IN PATIENTS WITH CYTOCHROME P450 2C19*2 GENE MUTATION AFTER PERCUTANEOUS CORONARY INTERVENTION. <i>Heart</i> , 2012, 98, E96.1-E96.	1.2	0

#	ARTICLE	IF	CITATIONS
378	An insight into the Interaction between Clopidogrel and Proton Pump Inhibitors. <i>Current Drug Metabolism</i> , 2012, 13, 225-235.	0.7	14
379	The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 169-175.	0.7	67
380	The growing importance of PON1 in cardiovascular health. <i>Journal of Cardiovascular Medicine</i> , 2012, 13, 443-453.	0.6	32
381	Clinical Outcomes Following Coronary Stenting in Japanese Patients Treated With and Without Proton Pump Inhibitor. <i>Circulation Journal</i> , 2012, 76, 71-78.	0.7	32
382	Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. <i>Heart</i> , 2012, 98, 100-108.	1.2	145
383	HPLC-MS/MS method for the simultaneous determination of clopidogrel, its carboxylic acid metabolite and derivatized isomers of thiol metabolite in clinical samples. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 911, 105-112.	1.2	47
384	Genetic and non-genetic factors affecting the response to clopidogrel therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 663-683.	0.9	38
385	Personalizing Antiplatelet Therapy With Clopidogrel. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 476-85.	2.3	12
386	Clopidogrel (Plavix), a P2Y ₁₂ receptor antagonist, inhibits bone cell function in vitro and decreases trabecular bone in vivo. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 2373-2386.	3.1	58
387	Breaking Resistance: Is There Still a Reason for Clopidogrel in Acute STEMI?. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 365-366.	1.3	0
388	Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention. <i>Heart</i> , 2012, 98, 1366-1372.	1.2	34
389	Relevancia clínica de la interacción clopidogrel y omeprazol: revisión sistemática. <i>Revista Colombiana De Cardiología</i> , 2012, 19, 25-32.	0.1	2
390	<i>Hematologic Diseases.</i> , 2012, , 350-368.		1
391	The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel <i>in vitro</i> . <i>British Journal of Pharmacology</i> , 2012, 166, 2362-2370.	2.7	18
392	Identification of High-Affinity P2Y ₁₂ Antagonists Based on a Phenylpyrazole Glutamic Acid Piperazine Backbone. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 8615-8629.	2.9	28
393	Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients with acute coronary syndrome in Taiwan. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 824-834.	1.1	20
394	CYP2C19*2/ABCB1-C3435T polymorphism and risk of cardiovascular events in coronary artery disease patients on clopidogrel: Is clinical testing helpful?. <i>Indian Heart Journal</i> , 2012, 64, 341-352.	0.2	24
395	Clinical Application of Cardiovascular Pharmacogenetics. <i>Journal of the American College of Cardiology</i> , 2012, 60, 9-20.	1.2	65

#	ARTICLE	IF	CITATIONS
396	The story of clopidogrel and its predecessor, ticlopidine: Could these major antiplatelet and antithrombotic drugs be discovered and developed today?. <i>Comptes Rendus Chimie</i> , 2012, 15, 737-743.	0.2	42
397	Synthesis and in vitro stability of nucleoside 5'-phosphonate derivatives. <i>European Journal of Medicinal Chemistry</i> , 2012, 54, 202-209.	2.6	8
398	Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y12 antagonists in an ex-vivo canine model. <i>Thrombosis Research</i> , 2012, 130, 622-628.	0.8	22
399	Receptors for Purines and Pyrimidines. , 2012, , 119-244.		1,005
400	Drug discovery for a new generation of covalent drugs. <i>Expert Opinion on Drug Discovery</i> , 2012, 7, 561-581.	2.5	140
401	Control of Oxidative Posttranslational Cysteine Modifications: From Intricate Chemistry to Widespread Biological and Medical Applications. <i>Chemical Research in Toxicology</i> , 2012, 25, 588-604.	1.7	86
402	Platelets in the pathogenesis of vascular disease and their role as a therapeutic target. , 2011, , 201-226.		2
403	Antiplatelet Drugs. <i>Chest</i> , 2012, 141, e89S-e119S.	0.4	318
404	Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response. <i>European Heart Journal</i> , 2012, 33, 2856-2864.	1.0	64
405	Differential Oxidation of Two Thiophene-Containing Regioisomers to Reactive Metabolites by Cytochrome P450 2C9. <i>Chemical Research in Toxicology</i> , 2012, 25, 895-903.	1.7	42
406	Recent advances in the pharmacogenetics of clopidogrel. <i>Human Genetics</i> , 2012, 131, 653-664.	1.8	26
407	P2Y12 receptors in platelets and other hematopoietic and non-hematopoietic cells. <i>Purinergic Signalling</i> , 2012, 8, 609-619.	1.1	114
408	Early double stent thrombosis associated with clopidogrel hyporesponsiveness. <i>Netherlands Heart Journal</i> , 2012, 20, 38-41.	0.3	3
409	Synthesis of N6-alkyl(aryl)-2-alkyl(aryl)thioadenosines as antiplatelet agents. <i>European Journal of Medicinal Chemistry</i> , 2012, 53, 114-123.	2.6	18
410	Association of Estimated GFR With Platelet Inhibition in Patients Treated With Clopidogrel. <i>American Journal of Kidney Diseases</i> , 2012, 59, 777-785.	2.1	52
411	Lack of clinically significant pharmacological interactions between ticagrelor and enoxaparin or unfractionated heparin in healthy subjects. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2012, 37, 704-711.	0.7	4
412	The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 199-206.	1.9	85
413	Toxicity of clopidogrel and ticlopidine on human myeloid progenitor cells: Importance of metabolites. <i>Toxicology</i> , 2012, 299, 139-145.	2.0	26

#	ARTICLE	IF	CITATIONS
414	Cardiovascular pharmacogenetics. , 2012, 133, 280-290.		19
415	Clopidogrel tapering as a strategy to attenuate platelet rebound phenomenon in patients with bare-metal stents. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 33, 16-21.	1.0	7
416	Influence of CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 771-777.	0.8	23
417	Clinical Impact of Genetically Determined Platelet Reactivity. <i>Journal of Cardiovascular Translational Research</i> , 2013, 6, 398-403.	1.1	6
418	CYP-Mediated Pharmacologic Interference with Optimal Platelet Inhibition. <i>Journal of Cardiovascular Translational Research</i> , 2013, 6, 404-410.	1.1	6
419	Clopidogrel resistance: Pre- vs post-receptor determinants. <i>Vascular Pharmacology</i> , 2013, 59, 152-161.	1.0	17
420	Conformationally Constrained ortho-Anilino Diaryl Ureas: Discovery of 1-(2-(1-Neopentylspiro[indoline-3,4-piperidine]-1-yl)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea, a Potent, Selective, and Bioavailable P2Y ₁ Antagonist. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 9275-9295.	2.9	60
421	Updates in Antiplatelet Agents Used in Cardiovascular Diseases. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2013, 18, 514-524.	1.0	23
422	Pharmacology of the New P2Y ₁₂ Receptor Inhibitors: Insights on Pharmacokinetic and Pharmacodynamic Properties. <i>Drugs</i> , 2013, 73, 1681-1709.	4.9	118
423	Hepatocellular toxicity of clopidogrel: Mechanisms and risk factors. <i>Free Radical Biology and Medicine</i> , 2013, 65, 208-216.	1.3	23
424	Pharmacogenomics in cardiovascular disease: focus on aspirin and ADP receptor antagonists. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1627-1639.	1.9	28
425	Clopidogrel reduces post-transplant obliterative bronchiolitis. <i>Transplant International</i> , 2013, 26, 1038-1048.	0.8	17
426	The P2Y ₁ receptors and thrombosis. <i>Environmental Sciences Europe</i> , 2013, 2, 241-253.	2.6	3
427	Lead Optimization of Ethyl 6-Aminonicotinate Acyl Sulfonamides as Antagonists of the P2Y ₁₂ Receptor. Separation of the Antithrombotic Effect and Bleeding for Candidate Drug AZD1283. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 7015-7024.	2.9	53
428	Assessing post-treatment platelet reactivity: a focus on patient selection and setting. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1557-1566.	0.6	1
429	Metabolic differences of current thienopyridine antiplatelet agents. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 307-317.	1.5	8
430	In Vitro Biotransformation Studies of 2-Oxo-clopidogrel: Multiple Thiolactone Ring-Opening Pathways Further Attenuate Prodrug Activation. <i>Chemical Research in Toxicology</i> , 2013, 26, 179-190.	1.7	18
431	Influence of genetic and non-genetic factors on the plasma concentrations of the clopidogrel metabolite (SR26334) among Chinese patients. <i>Clinica Chimica Acta</i> , 2013, 416, 50-53.	0.5	3

#	ARTICLE	IF	CITATIONS
432	Deuterated Clopidogrel Analogues as a New Generation of Antiplatelet Agents. ACS Medicinal Chemistry Letters, 2013, 4, 349-352.	1.3	65
433	Individualisation du traitement antiplaquettaire : quel est l'impact du monitoring plaquettaire ?. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2013, 2013, 35-41.	0.0	0
434	Pathways of platelet activation and unexplained clopidogrel variability: Causes of poor response to clopidogrel. Thrombosis Research, 2013, 132, 312.	0.8	6
435	Thienopyridine efficacy and cigarette smoking status. American Heart Journal, 2013, 165, 693-703.	1.2	12
436	Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms (CYP2C19, ABCB1, PON1), Noncompliance, Diet, Smoking, Co-Medications (Including) Tj ETQq0 0 0 r gBT /Overlock 10 T College of Cardiology, 2013, 61, 872-879.	1.2	170
437	The Role of Biotransformation Studies in Reducing Drug Attrition. Topics in Medicinal Chemistry, 2013, , 97-137.	0.4	2
438	Toxicity of thienopyridines on human neutrophil granulocytes and lymphocytes. Toxicology, 2013, 308, 11-19.	2.0	17
439	The Platelet P2 Receptors. , 2013, , 261-281.		11
440	ADP Receptor Antagonists. , 2013, , 1117-1138.		5
441	Establishment of a CYP2C19 Genotyping Assay for Clinical Use. American Journal of Clinical Pathology, 2013, 139, 202-207.	0.4	15
442	A validated HPLC-MS/MS assay for quantifying unstable pharmacologically active metabolites of clopidogrel in human plasma: Application to a clinical pharmacokinetic study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2013, 926, 36-41.	1.2	19
443	A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats. British Journal of Pharmacology, 2013, 169, 82-89.	2.7	30
444	Aromatic Sulfonyl Fluorides Covalently Kinetically Stabilize Transthyretin to Prevent Amyloidogenesis while Affording a Fluorescent Conjugate. Journal of the American Chemical Society, 2013, 135, 5656-5668.	6.6	142
445	The discovery and development of prasugrel. Expert Opinion on Drug Discovery, 2013, 8, 897-905.	2.5	7
446	Pharmacogenetic Advances in Cardiovascular Medicine: Relevance to Personalized Medicine. Current Genetic Medicine Reports, 2013, 1, 1-14.	1.9	4
447	Synthesis, structure-property relationships and pharmacokinetic evaluation of ethyl 6-aminonicotinate sulfonylureas as antagonists of the P2Y12 receptor. European Journal of Medicinal Chemistry, 2013, 65, 360-375.	2.6	36
448	Similarities and differences in the discovery and use of biopharmaceuticals and small-molecule chemotherapeutics. , 2013, , 161-203.		37
449	Antiplatelet Drug Use in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes. Postgraduate Medicine, 2013, 125, 51-58.	0.9	2

#	ARTICLE	IF	CITATIONS
450	CYP2C19 Genetic Polymorphism, Rabeprazole and Esomeprazole Have no Effect on the Antiplatelet Action of Clopidogrel. <i>Journal of Cardiovascular Pharmacology</i> , 2013, 62, 41-49.	0.8	9
451	Clopidogrel, Prasugrel, or Ticagrelor? A Practical Guide to Use of Antiplatelet Agents in Patients With Acute Coronary Syndromes. <i>Postgraduate Medicine</i> , 2013, 125, 91-102.	0.9	41
452	Formation, Reactivity, and Antiplatelet Activity of Mixed Disulfide Conjugates of Clopidogrel. <i>Molecular Pharmacology</i> , 2013, 83, 848-856.	1.0	14
453	Genetic and nongenetic factors influencing the response to clopidogrel. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, S1-S7.	0.6	19
454	Clopidogrel and warfarin pharmacogenetic tests. <i>Current Opinion in Cardiology</i> , 2013, 28, 305-314.	0.8	15
455	Pharmacogenomics Study of Clopidogrel by RFLP based Genotyping of CYP2C19 in Cardiovascular Disease Patients in North-East Population of India. <i>Journal of Pharmacogenomics & Pharmacoproteomics</i> , 2013, 05, .	0.2	2
456	Clopidogrel, CYP2C19, and a Black Box. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 241-248.	1.0	16
457	Targeting Platelet <sc>G</sc> Proteinâ€Coupled Receptors for Antithrombotic Therapy. <i>Drug Development Research</i> , 2013, 74, 440-449.	1.4	0
458	Population pharmacokinetic analysis of clopidogrel in healthy Jordanian subjects with emphasis optimal sampling strategy. <i>Biopharmaceutics and Drug Disposition</i> , 2013, 34, 215-226.	1.1	5
459	5-alkyl-1,3-oxazole derivatives of 6-amino-nicotinic acids as alkyl ester bioisosteres are antagonists of the P2Y₁₂ receptor. <i>Future Medicinal Chemistry</i> , 2013, 5, 2037-2056.	1.1	13
460	Pharmacodynamic Comparisons for Single Loading Doses of Prasugrel (30mg) and Clopidogrel (600mg) in Healthy Korean Volunteers. <i>Circulation Journal</i> , 2013, 77, 1253-1259.	0.7	17
461	The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 1-8.	0.7	130
462	Use of Antiplatelet Therapy after Percutaneous Coronary Intervention with Bare-Metal Stents and Different Types of Drug-Eluting Stents. <i>Current Clinical Pharmacology</i> , 2013, 8, 59-66.	0.2	0
463	Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways. <i>Thrombosis and Haemostasis</i> , 2013, 110, 1223-1231.	1.8	12
464	Comparison of antiplatelet effects of prasugrel and ticagrelor in cynomolgus monkeys by an ELISA-based VASP phosphorylation assay and platelet aggregation. <i>Thrombosis and Haemostasis</i> , 2013, 110, 769-776.	1.8	11
465	High on-treatment platelet reactivity (HPR): What does it mean, and does it matter?. <i>Thrombosis and Haemostasis</i> , 2013, 109, 177-178.	1.8	6
466	Pharmacokinetics of 600 mg loading dose of clopidogrel in patients undergoing percutaneous coronary intervention. <i>African Journal of Pharmacy and Pharmacology</i> , 2013, 7, 574-584.	0.2	2
467	Efficacy and Safety of Platelet Inhibitors. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2013, 16, 1.	0.9	10

#	ARTICLE	IF	CITATIONS
468	High on-treatment platelet reactivity and P2Y12 antagonists in clinical trials. <i>Thrombosis and Haemostasis</i> , 2013, 109, 834-845.	1.8	28
469	Personalized Medicine of Antithrombotic Therapy. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2013, 44, 219-224.	0.1	0
470	CYP2C19 Phenotype, Stent Thrombosis, Myocardial Infarction, and Mortality in Patients with Coronary Stent Placement in a Chinese Population. <i>PLoS ONE</i> , 2013, 8, e59344.	1.1	19
471	Microglial P2Y12 Deficiency/Inhibition Protects against Brain Ischemia. <i>PLoS ONE</i> , 2013, 8, e70927.	1.1	90
473	CYP-independent inhibition of platelet aggregation in rabbits by a mixed disulfide conjugate of clopidogrel. <i>Thrombosis and Haemostasis</i> , 2014, 112, 1304-1311.	1.8	6
474	Antiplatelet Effect of Clopidogrel Can Be Reduced by Calcium-Channel Blockers. <i>Yonsei Medical Journal</i> , 2014, 55, 683.	0.9	10
475	Efficacy versus safety: the dilemma of using novel platelet inhibitors for the treatment of patients with ischemic stroke and coronary artery disease. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 321.	0.9	5
476	Pharmacogenomics of Clopidogrel. , 2014, , 509-541.		1
477	Reducing Drug Attrition. <i>Topics in Medicinal Chemistry</i> , 2014, , .	0.4	3
478	The impact of smoking on clinical efficacy and pharmacodynamic effects of clopidogrel: a systematic review and meta-analysis. <i>Heart</i> , 2014, 100, 192-199.	1.2	21
479	Clopidogrel: What Is a Cardiologist to Do?. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 881-883.	1.0	2
480	4- <i>Benzo</i> thiazole-7- <i>hydroxy</i> indolyl Diaryl Ureas Are Potent P2Y ₁ Antagonists with Favorable Pharmacokinetics: Low Clearance and Small Volume of Distribution. <i>ChemMedChem</i> , 2014, 9, 2327-2343.	1.6	12
481	Clopidogrel, CYP2C19 and proton pump inhibitors: What we know and what it means. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 884-888.	1.0	8
482	CES1A \sim 816C as a Genetic Marker to Predict Greater Platelet Clopidogrel Response in Patients with Percutaneous Coronary Intervention. <i>Journal of Cardiovascular Pharmacology</i> , 2014, 63, 178-183.	0.8	19
483	Effects of Cyp2c19 and P2y12 Gene Polymorphisms on Clinical Results of Patients Using Clopidogrel After Acute Ischemic Cerebrovascular Disease. <i>Balkan Journal of Medical Genetics</i> , 2014, 17, 37-41.	0.5	14
484	Comparative bioavailability of two oral formulations of clopidogrel: Determination of clopidogrel and its carboxylic acid metabolite (SR26334) under fasting and fed conditions in healthy subjects. <i>Acta Pharmaceutica</i> , 2014, 64, 45-62.	0.9	8
485	Genetics of platelet inhibitor treatment. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 642-653.	1.1	37
486	Prevalence of Nonresponsiveness to Aspirin in Patients with Symptomatic Peripheral Arterial Disease Using True Point of Care Testing. <i>CardioVascular and Interventional Radiology</i> , 2014, 37, 631-638.	0.9	16

#	ARTICLE	IF	CITATIONS
487	The impact of germline mutations on targeted therapy. <i>Journal of Pathology</i> , 2014, 232, 230-243.	2.1	7
488	Clinical Pharmacokinetics of Clopidogrel and Its Metabolites in Patients with Cardiovascular Diseases. <i>Clinical Pharmacokinetics</i> , 2014, 53, 155-164.	1.6	80
489	Plant extracts inhibit ADP-induced platelet activation in humans: their potential therapeutic role as ADP antagonists. <i>Purinergic Signalling</i> , 2014, 10, 233-239.	1.1	11
490	In vitro interaction of clopidogrel and its hydrolysate with OCT1, OCT2 and OAT1. <i>International Journal of Pharmaceutics</i> , 2014, 465, 5-10.	2.6	13
491	Impact of CYP3A5 polymorphism on platelet reactivity at percutaneous coronary intervention and after 9 months of aspirin and clopidogrel therapy in Japanese patients with coronary artery disease. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 667-673.	0.8	11
492	New antiplatelet agents in the treatment of acute coronary syndromes. <i>Archives of Cardiovascular Diseases</i> , 2014, 107, 178-187.	0.7	14
493	Impact of CYP2C19 Polymorphism and Proton Pump Inhibitors on Platelet Reactivity to Clopidogrel and Clinical Outcomes Following Stent Implantation. <i>Thrombosis Research</i> , 2014, 133, 599-605.	0.8	40
494	HPCE AND HPLC METHODS FOR DETERMINATION OF CLOPIDOGREL AND ITS CARBOXYLIC ACID METABOLITE IN BIOLOGICAL SAMPLES: A COMPARATIVE ANALYSIS. <i>Journal of Liquid Chromatography and Related Technologies</i> , 2014, 37, 620-633.	0.5	3
495	Identification of alcoholâ€dependent clopidogrel metabolites using conventional liquid chromatography/triple quadrupole mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2014, 28, 1285-1292.	0.7	5
497	Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: a meta-analysis. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 1041-1047.	0.8	23
498	Synthesis of the stabilized active metabolite of clopidogrel. <i>Tetrahedron</i> , 2014, 70, 3893-3900.	1.0	12
499	Prodrugs and Drug Delivery Systems. , 2014, , 423-468.		1
500	Optimization of ketone-based P2Y12 receptor antagonists as antithrombotic agents: Pharmacodynamics and receptor kinetics considerations. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 2963-2968.	1.0	8
502	Front-loading with clopidogrel plus aspirin followed by dual antiplatelet therapy in the prevention of early stroke recurrence. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 723-734.	1.4	0
503	Thienopyridine P2Y12 receptor antagonists: unknown pharmacological active metabolites and metabolic activation mechanisms. <i>Drug Delivery System</i> , 2015, 30, 454-464.	0.0	0
504	A Randomized Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Clopidogrel in Three Different CYP2C19 Genotype Groups of Healthy Japanese Subjects. <i>Journal of Atherosclerosis and Thrombosis</i> , 2015, 22, 1186-1196.	0.9	13
505	Clopidogrel Response Variability. <i>American Journal of Therapeutics</i> , 2015, 22, 222-230.	0.5	10
506	The effect of acenocoumarol on the antiplatelet effect of clopidogrel. <i>Thrombosis and Haemostasis</i> , 2015, 114, 708-716.	1.8	3

#	ARTICLE	IF	CITATIONS
507	Delayed therapy with clopidogrel and everolimus prevents progression of transplant arteriosclerosis and impairs humoral alloimmunity in murine aortic allografts. <i>European Journal of Cardio-thoracic Surgery</i> , 2015, 47, 180-187.	0.6	23
508	Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies. <i>Drug Discovery Today</i> , 2015, 20, 1061-1073.	3.2	400
509	Medical Treatment of Stable Angina. <i>Cardiovascular Medicine</i> , 2015, , 421-459.	0.0	0
510	Inhibition of Cytochrome P450 Enzymes. , 2015, , 177-259.		46
511	Covalent Molecular Probes for Class A G Protein-Coupled Receptors: Advances and Applications. <i>ACS Chemical Biology</i> , 2015, 10, 1376-1386.	1.6	53
512	<i>CYP2C19</i> Metabolizer Status and Clopidogrel Efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) Study. <i>Journal of the American Heart Association</i> , 2015, 4, e001652.	1.6	44
513	Significant interethnic differences in functional variants of PON1 and P2RY12 genes in Roma and Hungarian population samples. <i>Molecular Biology Reports</i> , 2015, 42, 227-232.	1.0	5
514	Genetic polymorphisms of CYP2C19*2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome. <i>Gene</i> , 2015, 558, 200-207.	1.0	48
515	Clopidogrel Response Variability: Etiology and Clinical Relevance. <i>Current Cardiovascular Risk Reports</i> , 2015, 9, 1.	0.8	1
516	Future Translational Applications From the Contemporary Genomics Era. <i>Circulation</i> , 2015, 131, 1715-1736.	1.6	38
517	Clinical drug interaction profile of idelalisib in healthy subjects. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 909-919.	1.0	43
518	Cytochrome P450 bienzymes assembled on Au/chitosan/reduced graphene oxide nanosheets for electrochemically-driven drug cascade metabolism. <i>Electrochimica Acta</i> , 2015, 165, 36-44.	2.6	32
519	Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. <i>Lancet, The</i> , 2015, 386, 281-291.	6.3	209
520	Microvascular integrity plays an important role for graft survival after experimental skin transplantation. <i>Transplant Immunology</i> , 2015, 33, 204-209.	0.6	5
521	Human Liver Cytochrome P450 Enzymes and Microsomal Thiol Methyltransferase Are Involved in the Stereoselective Formation and Methylation of the Pharmacologically Active Metabolite of Clopidogrel. <i>Drug Metabolism and Disposition</i> , 2015, 43, 1632-1641.	1.7	27
522	Treatment and Prevention of Feline Arterial Thromboembolism. , 2016, , 369-378.		1
523	Significant Improvement of Metabolic Characteristics and Bioactivities of Clopidogrel and Analogs by Selective Deuteration. <i>Molecules</i> , 2016, 21, 704.	1.7	12
524	The Metabolism of Clopidogrel: CYP2C19 Is a Minor Pathway. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 1474-1483.	1.0	39

#	ARTICLE	IF	CITATIONS
525	Clopidogrel Improves Skin Microcirculatory Endothelial Function in Persons With Heightened Platelet Aggregation. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	6
526	Effects of omeprazole or pantoprazole on platelet function in non-ST-segment elevation acute coronary syndrome patients receiving clopidogrel. <i>Military Medical Research</i> , 2016, 3, 38.	1.9	1
527	Cytochrome allelic variants and clopidogrel metabolism in cardiovascular diseases therapy. <i>Molecular Biology Reports</i> , 2016, 43, 473-484.	1.0	14
528	Evaluation of Clopidogrel Conjugation Metabolism: PK Studies in Man and Mice of Clopidogrel Acyl Glucuronide. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1490-1497.	1.7	7
529	Concomitant Use of Proton Pump Inhibitors and Clopidogrel Is Not Associated with Adverse Outcomes after Ischemic Stroke in Chinese Population. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2016, 25, 2859-2867.	0.7	15
530	Cysteinome: The first comprehensive database for proteins with targetable cysteine and their covalent inhibitors. <i>Biochemical and Biophysical Research Communications</i> , 2016, 478, 1268-1273.	1.0	34
531	Ticagrelor regulates osteoblast and osteoclast function and promotes bone formation in vivo via an adenosine-dependent mechanism. <i>FASEB Journal</i> , 2016, 30, 3887-3900.	0.2	49
532	Pharmacogenomics and Global Precision Medicine in the Context of Adverse Drug Reactions: Top 10 Opportunities and Challenges for the Next Decade. <i>OMICS A Journal of Integrative Biology</i> , 2016, 20, 593-603.	1.0	20
533	The impact of P2Y12 promoter DNA methylation on the recurrence of ischemic events in Chinese patients with ischemic cerebrovascular disease. <i>Scientific Reports</i> , 2016, 6, 34570.	1.6	14
534	Omeprazole and atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation in patients undergoing percutaneous coronary intervention in a tertiary health care system: A prospective drug-drug interaction study. <i>IJC Metabolic & Endocrine</i> , 2016, 13, 35-40.	0.5	2
535	Preliminary Data from a Study on Polymorphism RS4244285 of P4502c19 Cytochrome Gene in Patients with Acute Coronary Syndrome, Undergoing Treatment with Dual Antiplatelet Therapy With Clopidogrel and Aspirin. <i>Journal of Biomedical and Clinical Research</i> , 2016, 9, 65-71.	0.1	0
536	Enhanced Platelet Response to Clopidogrel in Abcc3-deficient Mice Due to Its Increased Bioactivation. <i>Journal of Cardiovascular Pharmacology</i> , 2016, 68, 433-440.	0.8	12
537	Interleukin-10 does not modulate clopidogrel platelet response in mice. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 596-605.	1.9	11
538	Comparison of new adenosine diphosphate receptor antagonists with clopidogrel in patients with coronary artery disease: a meta-analysis. <i>Heart and Vessels</i> , 2016, 31, 275-287.	0.5	3
540	Gambogic acid potentiates clopidogrel-induced apoptosis and attenuates irinotecan-induced apoptosis through down-regulating human carboxylesterase 1 and -2. <i>Xenobiotica</i> , 2016, 46, 816-824.	0.5	9
541	Pivotal Bioequivalence Study of Clopacin [®] , a Generic Formulation of Clopidogrel 75mg Film-Coated Tablets. <i>Advances in Therapy</i> , 2016, 33, 186-198.	1.3	5
542	Pre-treatment with P2Y ₁₂ inhibitors in ACS patients: who, when, why, and which agent?. <i>European Heart Journal</i> , 2016, 37, 1284-1295.	1.0	52
543	Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 43-53.	1.0	4

#	ARTICLE	IF	CITATIONS
544	Prasugrel suppresses development of lithium-induced nephrogenic diabetes insipidus in mice. <i>Purinergic Signalling</i> , 2017, 13, 239-248.	1.1	10
545	The effectiveness and safety of dual antiplatelet therapy in ischemic cerebrovascular disease with intracranial and extracranial arteriostenosis in Chinese patients. <i>Medicine (United States)</i> , 2017, 96, e5497.	0.4	21
546	The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban,) <i>Tj ETQq0 0 0 rgBT, Overlock 2.0 Tf 50 6</i>	1.0	2
547	East Asian perspective on the interaction between proton pump inhibitors and clopidogrel. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1152-1159.	1.4	8
548	Use of Pharmacogenetic Information in the Treatment of Cardiovascular Disease. <i>Clinical Chemistry</i> , 2017, 63, 177-185.	1.5	9
549	PIK3CG single nucleotide polymorphisms are associated with poor responsiveness to clopidogrel and increased risk of ischemia in patients with coronary heart disease. <i>Medicine (United States)</i> , 2017, 96, e7566.	0.4	4
550	Developments in the synthesis of the antiplatelet and antithrombotic drug (<i><i>S</i></i>)â€œclopidogrel. <i>Chirality</i> , 2017, 29, 684-707.	1.3	23
551	Platelet receptors as therapeutic targets: Past, present and future. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1249-1257.	1.8	57
552	Advances in Antiplatelet Agents. , 2017, , 556-599.		1
553	Cardiovascular Drugs and Hemostasis. , 2018, , 561-589.		0
554	Mrp3 Transports Clopidogrel Acyl Glucuronide from the Hepatocytes into Blood. <i>Drug Metabolism and Disposition</i> , 2018, 46, 151-154.	1.7	8
555	Reversible, orally available ADP receptor (P2Y12) antagonists Part I: Hit to lead process. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 1459-1463.	1.0	6
556	A Literature Review of Genetic Markers Conferring Impaired Response to Cardiovascular Drugs. <i>American Journal of Cardiovascular Drugs</i> , 2018, 18, 259-269.	1.0	3
557	Cardiovascular Pharmacogenetics. , 2018, , 291-307.		0
558	Concomitant Use of Proton-Pump Inhibitors and Clopidogrel Increases the Risk of Adverse Outcomes in Patients With Ischemic Stroke Carrying Reduced-Function <i><i>CYP2C19*2</i></i> . <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 55-62.	0.7	12
559	Role of genetic testing in patients undergoing percutaneous coronary intervention. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 151-164.	1.3	57
560	The effects of signal transducer and activator of transcription three mutations on human platelets. <i>Platelets</i> , 2018, 29, 602-609.	1.1	2
561	17Î²-estradiol suppresses carboxylesterases by activating c-Jun/AP-1 pathway in primary human and mouse hepatocytes. <i>European Journal of Pharmacology</i> , 2018, 819, 98-107.	1.7	14

#	ARTICLE	IF	CITATIONS
562	Exploring PTDHâ€“P450BM3 Variants for the Synthesis of Drug Metabolites. ChemBioChem, 2018, 19, 326-337.	1.3	14
563	Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions. Drug Metabolism and Disposition, 2018, 46, 141-150.	1.7	22
564	Development and validation of a sensitive and rapid UHPLCâ€“MS/MS method for the simultaneous quantification of the common active and inactive metabolites of vicagrel and clopidogrel in human plasma. Journal of Pharmaceutical and Biomedical Analysis, 2018, 149, 394-402.	1.4	15
565	Percutaneous pleural drainage in patients taking clopidogrel: real danger or phantom fear?. Journal of Thoracic Disease, 2018, 10, 5162-5169.	0.6	3
566	STEREOCHEMISTRY - RACEMIC MODIFICATION, RESOLUTION, AND ITS IMPORTANCE WITH RECENTLY USED OPTICALLY ACTIVE DRUGS.. Asian Journal of Pharmaceutical and Clinical Research, 2018, 11, 3.	0.3	0
567	Laboratory monitoring of P2Y12 inhibitors: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2018, 16, 2341-2346.	1.9	11
568	MWCNT/CdSe quantum dot modified glassy carbon electrode for the determination of clopidogrel bisulfate in tablet dosage form and serum samples. Journal of Electroanalytical Chemistry, 2018, 827, 51-57.	1.9	13
569	Dynamic States of the Ligand-Free Class A G Protein-Coupled Receptor Extracellular Side. Biochemistry, 2018, 57, 4767-4775.	1.2	2
570	A synergic effect between CYP2C19*2, CYP2C19*3 loss-of-function and CYP2C19*17 gain-of-function alleles is associated with Clopidogrel resistance among Moroccan Acute Coronary Syndromes patients. BMC Research Notes, 2018, 11, 46.	0.6	10
572	Natural polysaccharides for growth factors delivery. , 2019, , 495-512.		3
573	Exploiting Cysteine Residues of SLC Membrane Transporters as Targets for Drugs. SLAS Discovery, 2019, 24, 867-881.	1.4	10
574	Platelets in chronic liver disease, from bench to bedside. JHEP Reports, 2019, 1, 448-459.	2.6	48
575	Switching between P2Y12 antagonists â€“ From bench to bedside. Vascular Pharmacology, 2019, 115, 1-12.	1.0	8
576	The clinical effects of CYP2C19 *2 allele frequency on Palestinian patients receiving clopidogrel after percutaneous coronary intervention. International Journal of Clinical Pharmacy, 2019, 41, 96-103.	1.0	6
577	Influence of CYP450 Enzymes, CES1, PON1, ABCB1, and P2RY12 Polymorphisms on Clopidogrel Response in Patients Subjected to a Percutaneous Neurointervention. Clinical Therapeutics, 2019, 41, 1199-1212.e2.	1.1	23
578	Statins significantly reduce mortality in patients receiving clopidogrel without affecting platelet activation and aggregation: a systematic review and meta-analysis. Lipids in Health and Disease, 2019, 18, 121.	1.2	10
579	Enhanced Platelet Response to Clopidogrel in Zucker Diabetic Fatty Rats due to Impaired Clopidogrel Inactivation by Carboxylesterase 1 and Increased Exposure to Active Metabolite. Drug Metabolism and Disposition, 2019, 47, 794-801.	1.7	7
580	Genotype-guided personalization of antiplatelet treatment: A meta-analysis of patients with ACS or undergoing PCI. Thrombosis Research, 2019, 179, 87-94.	0.8	8

#	ARTICLE	IF	CITATIONS
581	Coronary Revascularization in Patients With Advanced Chronic Kidney Disease. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1002-1014.	0.8	7
582	Pharmacodynamic changes of platelet reactivity status in patients with chronic kidney disease after coronary artery stenting. <i>Biomedicine and Pharmacotherapy</i> , 2019, 113, 108773.	2.5	3
583	Association between CYP2C19*2/*3 Polymorphisms and Coronary Heart Disease. <i>Current Medical Science</i> , 2019, 39, 44-51.	0.7	8
584	The Platelet P2 Receptors. , 2019, , 259-277.		3
585	P2Y12 Antagonists. , 2019, , 937-956.		1
586	Adenosine and the Cardiovascular System. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 449-464.	1.0	67
587	Oral antiplatelets in primary and secondary prevention of myocardial infarction: a review. <i>Irish Journal of Medical Science</i> , 2019, 188, 453-467.	0.8	4
588	Oral administration of leeches (Shuizhi): A review of the mechanisms of action on antiplatelet aggregation. <i>Journal of Ethnopharmacology</i> , 2019, 232, 103-109.	2.0	18
589	Bioavailability enhanced clopidogrel -loaded solid SNEDDS: Development and in-vitro/in-vivo characterization. <i>Journal of Drug Delivery Science and Technology</i> , 2019, 49, 603-614.	1.4	31
590	<i>CYP2C19</i> pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta-analysis of randomized clinical trials. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 1246-1252.	0.7	27
591	Cost-effectiveness analysis of pharmacogenomics-guided clopidogrel treatment in Spanish patients undergoing percutaneous coronary intervention. <i>Pharmacogenomics Journal</i> , 2019, 19, 438-445.	0.9	18
592	Pharmacokinetics and pharmacokinetic/pharmacodynamic relationship of vicagrel, a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy Chinese subjects following single oral dosing. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 127, 151-160.	1.9	13
593	Influence of <i>CYP2C19</i> Phenotype on the Effect of Clopidogrel in Patients Undergoing a Percutaneous Neurointervention Procedure. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 661-671.	2.3	16
594	Inhibition of carboxylesterase-1 alters clopidogrel metabolism and disposition. <i>Xenobiotica</i> , 2020, 50, 245-251.	0.5	5
595	Involvement of P2 receptors in hematopoiesis and hematopoietic disorders, and as pharmacological targets. <i>Purinergic Signalling</i> , 2020, 16, 1-15.	1.1	13
597	Type 2 diabetes mellitus decreases systemic exposure of clopidogrel active metabolite through upregulation of P-glycoprotein in rats. <i>Biochemical Pharmacology</i> , 2020, 180, 114142.	2.0	7
599	Covalent allosteric modulation: An emerging strategy for GPCRs drug discovery. <i>European Journal of Medicinal Chemistry</i> , 2020, 206, 112690.	2.6	15
600	One-Step Fabrication of Electrochemical Reduced Graphene Oxide-Carboxyl Functionalized Multiwalled Carbon Nanotubes Film and Its Use as a Platform for Determination of Clopidogrel Bisulfate. <i>Nano</i> , 2020, 15, 2050130.	0.5	1

#	ARTICLE	IF	CITATIONS
601	Antiplatelet Drugs for Neurointerventions: Part 1 Clinical Pharmacology. <i>Clinical Neuroradiology</i> , 2020, 30, 425-433.	1.0	5
602	Approaches for designing and discovering purinergic drugs for gastrointestinal diseases. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 687-703.	2.5	9
603	Safety and Pharmacokinetics of DS 1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 691-701.	1.0	4
604	Pharmacokinetics and Pharmacodynamics of Approved and Investigational P2Y ₁₂ Receptor Antagonists. <i>Clinical Pharmacokinetics</i> , 2020, 59, 545-566.	1.6	44
605	CYP2C19 and CYP3A4 activity and ADP-induced platelet reactivity in prasugrel- or ticagrelor-treated STEMI patients: monocentric study in PRAGUE-18 trial participants. <i>Xenobiotica</i> , 2020, 50, 929-938.	0.5	4
606	Impacts of CYP2C19 genetic polymorphisms on bioavailability and effect on platelet adhesion of ticagrelor, a novel thienopyridine P2Y ₁₂ inhibitor. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1860-1874.	1.1	12
607	The Role of Clopidogrel in 2020: A Reappraisal. <i>Cardiovascular Therapeutics</i> , 2020, 2020, 1-12.	1.1	55
608	Clopidogrel Resistance in a Murine Model of Diet-Induced Obesity Is Mediated by the Interleukin-1 Receptor and Overcome With DT-678. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 1533-1542.	1.1	8
609	Pharmacodynamics and Pharmacokinetics of Stroke Therapy. , 2021, , 41-69.		0
610	Commonly Prescribed Medications that Affect Clotting: A Comprehensive Overview. , 2021, , 167-190.		0
611	Characteristics of Major Drug Metabolizing Cytochrome P450 Enzymes. <i>Methods in Pharmacology and Toxicology</i> , 2021, , 27-54.	0.1	2
612	Association of CYP2C19 Loss-of-Function Alleles with Major Adverse Cardiovascular Events of Clopidogrel in Stable Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention: Meta-analysis. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 1147-1159.	1.3	15
613	The potential interaction of statins and clopidogrel in patients undergoing percutaneous coronary intervention. <i>International Journal of Advanced and Applied Sciences</i> , 2021, 8, 112-119.	0.2	0
615	A Pharmacogenetic Study of CYP2C19 in Acute Coronary Syndrome Patients of Colombian Origin Reveals New Polymorphisms Potentially Related to Clopidogrel Therapy. <i>Journal of Personalized Medicine</i> , 2021, 11, 400.	1.1	4
616	Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 963-978.	1.3	27
617	Clopidogrel in noncarriers of CYP2C19 loss-of-function alleles versus ticagrelor in elderly patients with acute coronary syndrome: A pre-specified sub analysis from the POPular Genetics and POPular Age trials CYP2C19 alleles in elderly patients. <i>International Journal of Cardiology</i> , 2021, 334, 10-17.	0.8	4
618	Electrical impedance vs. light transmission aggregometry: Testing platelet reactivity to antiplatelet drugs using the MICELI POC impedance aggregometer as compared to a commercial predecessor. <i>Thrombosis Research</i> , 2021, 204, 66-75.	0.8	1
619	Oxidative metabolism of razuprotafib (AKB-9778), a sulfamic acid phosphatase inhibitor, in human microsomes and recombinant human CYP2C8 enzyme. <i>Xenobiotica</i> , 2021, 51, 1110-1121.	0.5	2

#	ARTICLE	IF	CITATIONS
620	Biologically active metabolites in drug discovery. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 48, 128255.	1.0	3
621	Recommended tool compounds and drugs for blocking P2X and P2Y receptors. <i>Purinergic Signalling</i> , 2021, 17, 633-648.	1.1	21
622	<i>Cardiovascular Drugs and Hemostasis</i> . , 2022, , 701-729.		1
625	<i>Stroke Prevention With Antiplatelet Therapy</i> . , 2004, , 117-137.		1
626	<i>Thrombosis</i> . , 2006, , 125-133.		2
627	How Physicochemical Properties of Drugs Affect Their Metabolism and Clearance. <i>RSC Drug Discovery Series</i> , 2015, , 1-26.	0.2	9
630	Platelet P2Y12 Is Involved in Murine Pulmonary Metastasis. <i>PLoS ONE</i> , 2013, 8, e80780.	1.1	77
631	Association of PON1, P2Y12 and COX1 with Recurrent Ischemic Events in Patients with Extracranial or Intracranial Stenting. <i>PLoS ONE</i> , 2016, 11, e0148891.	1.1	29
632	Current Antithrombotic Therapy in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Interventions. <i>Interventional Cardiology Review</i> , 2011, 9, 94.	0.7	3
633	The influence of diabetic status on the pharmacokinetics of clopidogrel and its metabolites in patients suffered from cardiovascular diseases. <i>Journal of Medical Science</i> , 2014, 83, 215-221.	0.2	1
634	Freeze-Dried Clopidogrel Loaded Lyotropic Liquid Crystal: Box-Behnken Optimization, In-Vitro and In-Vivo Evaluation. <i>Current Drug Delivery</i> , 2020, 17, 207-217.	0.8	8
635	Novel Strategies in Anti-Platelet Treatment for Coronary Artery Disease. <i>Vascular Disease Prevention</i> , 2009, 6, 75-84.	0.2	5
636	Combined Antiplatelet Therapy: Still a Sweeping Combination in Cardiology. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2013, 11, 136-167.	0.4	6
637	<i>Alternative Toxicity of Phthalates</i> . , 2013, 03, .		1
638	<i>CYP<i>2C19 (+ or i4)*2/(+ or i4)*17 Diplotypes: Prognostic impactson patients with acute coronary syndrome. <i>World Journal of Cardiovascular Diseases</i> , 2012, 02, 260-268.	0.0	1
639	The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation. <i>EuroIntervention</i> , 2013, 9, 316-327.	1.4	36
641	2â€Šubstituted thienotetrahydropyridine derivatives: Allosteric ectonucleotidase inhibitors. <i>Archiv Der Pharmazie</i> , 2021, 354, e2100300.	2.1	4
644	<i>Prevention and Management of Thromboembolism</i> . , 2006, , 331-345.		0

#	ARTICLE	IF	CITATIONS
645	Clpidogrel 75 mg once daily in combination with aspirin for secondary prevention of atherothrombotic events in patients with acute coronary syndrome: a randomized controlled trial. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2009, 40, 261-265.		
647	2. Genetic Polymorphism of CYP2C19 Affects Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Subjects. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2009, 40, 261-265.	0.1	0
648	Overview of Platelet-Dependent Thrombosis. <i>Fundamental and Clinical Cardiology</i> , 2009, , 9-18.	0.0	2
649	Platelets in Arterial Thrombosis. , 2010, , 3-17.		1
650	Clopidogrel resistance. <i>Nosotchu</i> , 2010, 32, 740-745.	0.0	0
652	Efeitos da terapia combinada atorvastatina e clopidogrel na biodisponibilidade da estatina e na funĂo plaquetria em pacientes com doenĂa coronria estvel. <i>Revista Brasileira De Cardiologia Invasiva</i> , 2010, 18, 185-192.	0.1	0
653	The effectiveness of clopidogrel in the prevention of thrombotic complications in patients with acute coronary syndrome and genetic factors. <i>Kazan Medical Journal</i> , 2012, 93, 294-297.	0.1	1
656	Pharmacogenomic Testing of Anti-Platelets Drugs and its Cost- Effectiveness. , 2013, 03, .		2
657	Pharmacogenomics and Personalized Medicine of the Antiplatelet Drugs. , 2013, , 469-506.		0
658	Hemostasis and Thrombosis. , 2013, , 602-611.		1
659	Antiplatelet Agents in Diabetic Patients: Clinical Advances and Remaining Questions. <i>Journal of Clinical & Experimental Cardiology</i> , 2014, 05, .	0.0	0
661	Risk Factor Analysis for Incidence of Major Adverse Cardiac Events after Percutaneous Coronary Intervention Treatment. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , 2014, 40, 278-284.	0.0	0
662	Evaluation of the Relative Efficacy and Safety of Prasugrel and Clopidogrel in Medically Managed High Risk UA/NSTEMI ACS Population. <i>International Journal of Medical and Dental Sciences</i> , 2015, 4, 809.	0.1	0
663	Role of Antiplatelet Therapy in Neurosurgery: Efficacy and Safety Profiles. , 2016, , 65-89.		0
664	Overview of Platelet-Dependent Thrombosis. , 2016, , 31-40.		0
665	Biomedical applications of polysaccharides. , 2020, , 1-34.		2
666	Chemical Approaches for Studying the Biology and Pharmacology of Membrane Transporters: The Histidine/Large Amino Acid Transporter SLC7A5 as a Benchmark. <i>Molecules</i> , 2021, 26, 6562.	1.7	5
667	Antiplatelet Drugs. , 2005, , 203-218.		0

#	ARTICLE	IF	CITATIONS
668	Perspective on Improving the Relevance, Rigor, and Reproducibility of Botanical Clinical Trials: Lessons Learned From Turmeric Trials. <i>Frontiers in Nutrition</i> , 2021, 8, 782912.	1.6	4
669	The Platelet Inhibitory Effects and Pharmacokinetics of Prasugrel After Administration of Loading and Maintenance Doses in Healthy Subjects. <i>Journal of Cardiovascular Pharmacology</i> , 2006, 47, 377-384.	0.8	84
672	Synthesis and biological study of new galanthamine-peptide derivatives designed for prevention and treatment of Alzheimer's disease. <i>Amino Acids</i> , 2022, 54, 897-910.	1.2	1
673	Phenotypic drug discovery: recent successes, lessons learned and new directions. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 899-914.	21.5	81
674	Pleiotropic effects of clopidogrel. <i>Purinergic Signalling</i> , 2022, 18, 253-265.	1.1	4
675	Reinvestigation of clopidogrel bioactivation unveils new cytochrome P450-catalyzed thioester cleavage mechanism. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 72, 128872.	1.0	1
676	Antibiotics-induced disruption of gut microbiota increases systemic exposure of clopidogrel active metabolite in type 2 diabetic rats. <i>Drug Metabolism and Disposition</i> , 0, , DMD-AR-2022-000906.	1.7	0
677	Advances in covalent drug discovery. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 881-898.	21.5	187
678	Novel approaches to antiplatelet therapy. <i>Biochemical Pharmacology</i> , 2022, 206, 115297.	2.0	4
679	Development and Validation of a Bioanalytical Method for the Quantification of Clopidogrel in Human Plasma by LC-MS/MS using the Accuracy Profiles. <i>Methods and Objects of Chemical Analysis</i> , 2022, 17, 153-161.	0.4	0
681	Genotyping genetic variants of <i>CYP2C19</i> for precision antiplatelet dosing: state of the art and future perspectives. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022, 18, 817-830.	1.5	1
682	Decreased plasma exposure of clopidogrel active metabolite in rats after long-term treatment with clopidogrel. <i>Biopharmaceutics and Drug Disposition</i> , 0, , .	1.1	0
683	Cytochrome P450 2C19 Polymorphisms and Its Association With Major Adverse Cardiac Events in Post-coronary Intervention Patients on Clopidogrel in the Tertiary Care Center. <i>Cureus</i> , 2023, , .	0.2	0